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ABSTRACT 
 
SYNTHESIS OF A POTENTIALLY INSULIN-MIMETIC, LIPID-LINKED INOSITOL 
GLYCAN 
by Meenakshi Goel 
 
Inositol glycans (IGs) are naturally occurring oligosaccharides that can stimulate 
insulin sensitive cells.  Several synthetic IG analogues have been shown to activate the 
insulin-signaling pathway, including the stimulation of the enzyme pyruvate 
dehydrogenase (PDH) phosphatase that can further stimulate aerobic metabolism in cells. 
Cancer cells shift to anaerobic metabolism in order to escape intrinsic apoptosis 
(Warburg Effect).  IG’s ability to stimulate aerobic metabolism might provide a method 
to reverse the Warburg Effect and thereby induce apoptosis in the cancer cells.  One 
specific palmitoylated IG analogue has been shown to selectively kill cancer cells while 
having no adverse effect on normal cells.  However, this analogue is unstable under 
physiological conditions due to ester hydrolysis and acyl group migration.   
This thesis describes the work on the synthesis of an IG analogue in which the ester 
linkage has been replaced by ether.  Since ethers are comparatively more stable than 
esters, the resulting IG analogue should be more stable than the parent analogue.  
Biological activity of this IG analogue will be reported elsewhere.
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CHAPTER 1 
INTRODUCTION 
 
1.1  GLYCOSYLPHOSPHATIDYLINOSITOLS (GPIs) AND INOSITOL-
PHOSPHOGLYCANS (IPGs)  
 
1.1.1 Glycosylphosphatidylinositols (GPIs) 
GPIs are a group of naturally occurring glycolipids that are classified into two 
categories, GPI-anchors or free-GPIs, depending upon the presence or absence, 
respectively, of proteins at the terminal end of GPI molecule.  GPIs are ubiquitous in 
eukaryotes, including vertebrates, plants, mollusca, insects, schistosomes, fungi, and 
protozoa.1  The main function of GPI-anchors is to anchor certain molecules and proteins 
to the extracellular surface of the plasma membrane.  The biochemistry and functional 
significance of these structures have been explored in detail since the 1980’s.2-5  
Although GPI-anchors serve primarily as an alternative to hydrophobic trans-membrane 
polypeptide anchors, several other functions have been proposed for these structures.  
These include roles in intracellular sorting, cell communication, trans-membrane 
signaling or as soluble mediators of hormone action.   Several reviews have been 
published that describe these functions in detail.3,6,7  Hydrolysis products of GPIs are 
known as inositol-phosphoglycans (IPGs), inositol glycans (IGs) or 
phosphatidylinositolglycans (PIGs).  IPGs mimic some of the bioactivities of hormones 
and cytokines like insulin, nerve growth factor, transforming growth factor-β, interleukin-
  2
2, thyrotropin, follicle stimulating hormone and chorionic gonadotropin.  Binding of 
these hormones to their respective receptors results in the hydrolysis of GPIs and the 
release of IPGs that serve as second messengers, mediating the signal-transduction 
pathways of the respective hormones or cytokines.8  Thus, an understanding of the 
chemical structures of GPIs and their hydrolysis products might help in understanding 
several biological events occurring in living systems.  
 
1.1.2  Structural relationship between GPIs and IPGs 
Much effort has been expended to elucidate the chemical structures of GPI-
anchors.  The first GPI-anchor to be determined in detail was that of T. brucei in 1988 
(Figure 1).1  Since then, the structure of several natural GPI-anchors has been determined 
including those from S. cerevisiae,9 rat brain Thy-1,10 and T. gondii.11  All GPIs have 
similar chemical structures, with minor differences among different species.12  The 
common core of a GPI molecule is composed of a sugar moiety, a phosphatidylinositol 
(PI) moiety, and a terminal hydrophobic moiety that anchors the GPI molecule into the 
cell membrane.  The sugar moiety (or “glycan core”) is composed of a glucosamine 
(GlcN), three mannose residues, and one phospho-ethanolamine residue that can form an 
amide bond with the C-terminus of a polypeptide.  The reducing end of GlcN is 
glycosidically linked to PI.  PI is then linked to the hydrophobic moiety through a 
phospho-diester linkage.  A variety of lipids such as 1,2-diacylglycerol, 1-alkyl-2-
acylglycerol, monoacylglycerol, and ceramide can be utilized as the hydrophobic moiety 
in the GPI molecule.   
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Thus all GPI-anchors are arranged in a conserved sequence: Protein – 
Ethanolamine - PO4 - 6 Man α l-2 Man α l-6 Man α l-4 GlcN α l-6 myo- inositol – PO4 - 
lipid (Figure 1).  In many GPI-anchors, one or more side chains, like monosaccharides, 
oligosaccharides or phospho-ethanolamine groups, may further modify the GPI glycan 
core.13 
VSG Protein   NH   CH2   CH2   O    P    O
Manα1-2 Manα1-6 Manα1-4 GlcNH2α1-6 myo-inositol H2
C CH CH2
O
O
O
O
Galα1-3
Galα1-6 Galα1-2
Galα1-2
Galactose side chain
Conserved glycan core
PI moiety
O
OPO
O
 
 
Hydrolysis of GPI-anchors with certain proteases or hydrolases releases the 
terminal proteins, giving free-GPIs.  Both GPI-anchors and free-GPIs can further undergo 
lipolytic hydrolysis by the action of enzymes called phospholipases to release free IPGs.  
Phosphatidylinositol-specific phospholipase C (PI-PLC) hydrolyzes the phosphodiester 
bond of phosphatidylinositol to form 1,2-diacylglycerol and glycopeptide-bound (in GPI-
anchor) or glycan-bound (in free-GPI) inositol-1, 2- cyclic- phosphate (Figure 2).14  
Glycan-bound PI molecules, called IPGs, can be internalized into the cytosol via certain 
Figure 1. Structure of the GPI anchor of T. brucei. 
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IG transporters in the cell membrane and function as “second messengers” of hormone 
action.6  Evidence in favor of this behavior comes from the fact that exogenous addition 
of bacterial PI-PLC has been shown to generate insulin-mimetic compounds.15 
 
Gln
Man
Man
Protein
GPI Anchor
Etn
Man
Gln
Man
Man
Etn
Man
GPI
GPI-PLC
InsIns
Membrane bilayer
GPI-PLD
P
P
P
P
 
 
 
Some GPI anchors contain an additional fatty acid group (usually palmitoyl) 
attached to the C-2 position of the inositol moiety.16  This additional group renders the 
anchor resistant to the cleavage with PI-PLC.17  However, extracellular 
glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) can hydrolyze GPI-
anchors and free-GPIs with acylated inositols.18  The hydrolysis products of GPI-PLD are 
phosphatidic acid and IPG lacking a cyclic phosphate.19  Based on the structural 
similarity between IPGs and hydrolyzed products of GPIs, it has been speculated that 
Figure 2. Cleavage of GPI anchor/ GPI with PI-PLC / GPI-PLC or with GPI-PLD. 
               (“Etn” equals ethanolamine).   
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IPGs are generated by hydrolysis of GPIs.  However, the exact source of IPGs is not yet 
known. 
 
1.1.3  Inositol glycans (IGs): Putative second messengers of insulin action 
IPGs and IGs are structurally similar to the protein-linked GPI anchors, with the 
only difference being the absence of the protein fragment and the lipid moiety.  A close 
relationship between IGs and GPIs was confirmed by the observation that treatment of 
GPI-anchored variant surface glycoprotein (VSG) with PI-PLC (for lipid cleavage) and 
pronase (for protein cleavage) resulted in a fragment with significant insulin-like activity 
in rat hepatocytes and adipocytes.20,21  Further studies revealed the presence of two 
different types of IPGs, IPG-type A (containing a myo-inositol and glucosamine)22 and 
IPG-type P (containing chiro-inositol and galactosamine).23  Jones and coworkers 
reviewed comparative studies of two types of IPGs in 1998.7  Both the IPGs, when added 
exogenously, were found to mimic certain actions of insulin.  Intravenous administration 
of either IPG type A or P to streptozotocin treated diabetic rats reversed hyperglycemia in 
a manner similar to insulin, thus suggesting a role for IPGs as second messengers of 
insulin action.24  
The first natural IG (an IPG-A type) 1 was isolated in 1986 by the treatment of 
bovine liver with insulin (Figure 3).15  This natural IG stimulated insulin-sensitive cells 
even in the absence of insulin, thus suggesting its role as a second messenger in insulin 
action.25  Since then, several research groups have been involved in the isolation and 
purification of natural IGs in order to understand their biological functions in detail.26-28  
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The first natural IPG-P type IG 2 was characterized in 2003 (Figure 3).29  This pseudo-
disaccharide was found to be a putative insulin mediator that activated PDH phosphatase.  
The presence of a β-1, 4 linkage between pinitol and galactosamine was noteworthy 
because all naturally occurring GPI structures previously studied have an α-1, 6 linkage 
between glucosamine and myo-inositol. 
O
OH
HO
H2N
OH
O
O
OHHO
OH
OH
H3C
Mn2+
1
2
OHO
HO
OH
O
OHO
HO
OH
O
HO
HO
O
OO
HO
O
NH3
OH
O
OHO
OH
OH
P
O O
O
OH
P
O
OO
H2N
 
 
 
 
Several sub-cellular assays have been done to explore the insulin-mimetic 
activities of IGs and to discover their role as second messengers of insulin action.30-32  
However, before unraveling the role of IPGs in insulin action, it is first important to 
understand the role of insulin and its signaling mechanism.     
 
 
Figure 3. Compound 1: Structure of VSG anchor fragment (IPG-A type) from T. bruceii 
variant 118; Compound 2: Structure of natural and fully characterized IPG-P type IG 
analogue. 
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1.2  OVERVIEW OF INSULIN SIGNALING 
 Insulin is a hormone released by pancreatic beta cells in response to elevated 
levels of nutrients in the blood.  Insulin triggers the uptake of glucose, fatty acids and 
amino acids into adipose tissue, muscle and the liver and promotes the storage of these 
nutrients in the form of glycogen, lipids, and protein, respectively.  Insulin is linked to 
cellular metabolism via the insulin receptor (IR) located on the surface of certain insulin-
sensitive cells like hepatocytes, adipocytes and muscle cells.33  IR is a heterotetrameric 
transmembrane glycoprotein, composed of two extracellular α-subunits and two 
transmembrane β-subunits linked together by disulfide bonds.  Activation of IR triggers a 
cascade of interrelated metabolic pathways regulated by different mechanisms.  The 
interdependency of metabolic events in the insulin-signaling pathway has hindered efforts 
to understand fully the nature of insulin action.  Due to the complexity of the molecular 
mechanisms by which insulin elicits its numerous metabolic responses, insulin signaling 
have been the subject of intense research over the past several decades.33,34   
The intricate pathway of insulin signaling is depicted in Figure 4.35  Once secreted 
from the beta cells of pancreas, insulin binds to the insulin receptors (IRs) (1).  Binding 
of insulin to the α-subunit of IR induces a conformational change resulting in the 
autophosphorylation of a number of tyrosine residues present in the β-subunit (2).  
Receptor activation leads to the phosphorylation of key tyrosine residues on insulin 
receptor substrate (IRS) proteins, some of which are recognized by the Src homology 2 
(SH2) domain of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-K), a 
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lipid kinase (3).  The catalytic subunit of PI 3-kinase, p110, then phosphorylates 
phosphatidylinositol (4,5) bisphosphate (PIP2) (4) and (5) leads to the formation of 
phosphatidylinositol (3,4,5) trisphosphate (PIP3) (6).  A key downstream substrate of 
elevated concentrations of PIP3 is Akt or protein kinase B (PKB), which is confined to 
the plasma membrane.  Phosphorylation and activation of Akt (7) and (8) requires two 
different kinases: phosphoinositide-dependent kinase 1 (PDK1), and a recently identified 
mTOR-RICTOR protein complex called PDK 2.36  Once active, Akt is responsible for 
regulation of various metabolic pathways via phosphorylations.  Akt catalyzes 
phosphorylation of glycogen synthase kinase 3 (GSK-3) (9) that leads to inactivation of 
GSK-3 (10) that in turn prevents phosphorylation and inactivation of glycogen synthase 
(GS) (11), the major substrate of GSK-3, resulting in increased glycogen synthesis.  PIP3 
also activates protein phosphatase 1 (PP1), localized on glycogen particles, that in turn 
dephosphorylates inactive GS (13) and converts it into active GS (12), thus further 
increasing glycogen synthesis.   
 In addition to glucose uptake and storage, insulin also promotes the uptake of 
fatty acids and synthesis of lipids.  Lipid biosynthesis is indirectly an outcome of glucose 
metabolism.  Inactivation of GSK-3 inhibits phosphorylation of ATP citrate lyase (ACL) 
at one site (14).  However, phosphorylation of this enzyme at another site by PKB (15) 
enhances its activity, thus increasing the conversion of citrate to acetyl-CoA in cytosol 
(16), where it can be utilized in lipid biosynthesis.  
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Another key action of insulin is to stimulate glucose uptake into cells by inducing 
translocation of the glucose transporter, GLUT4, from intracellular storage to the plasma 
membrane.37  PI 3-kinase and Akt are known to play a role in GLUT4 translocation, (17) 
and (18).  In addition, a PI 3-kinase-independent pathway provides a second cue for 
GLUT4 recruitment to the plasma membrane.34  In this pathway, IR activation (19) leads 
to the phosphorylation of Cbl (20), which exists as a complex with Cb1 associated 
protein (CAP).  Following phosphorylation (21), the Cbl-CAP complex translocates to 
Figure 4. Schematic representation of insulin signaling transduction (Reproduced 
from Future Medicinal Chemistry (2009), 1(1), 95-118 with permission of Future 
Science Ltd). 
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lipid rafts in the plasma membrane.  Cbl then interacts with the adaptor protein CrkII 
(22), which is constitutively associated with the Rho-family guanine nucleotide exchange 
factor, C3G.  C3G in turn activates members of the GTP-binding protein family, TC10 
(23), which promote GLUT4 translocation to the plasma membrane via an unknown 
mechanism (24).  It is hypothesized that this happens via actin cytoskeleton regulation - a 
function attributed to many of the Rho proteins.38 
Two other metabolic events controlled by insulin include inhibition of lipolysis 
and gluconeogenesis.  Insulin inhibits lipolysis by decreasing cellular concentrations of 
cAMP, by activating a cAMP specific phosphodiesterase 3B (PDE3B) in adipocytes [(25) 
and (26)].39  Activated PDE3B hydrolyzes cAMP (27).  Low cAMP level reduces the 
activity of protein kinase A (PKA) (28), which in turn is unable to phosphorylate and 
activate hormone sensitive lipase (HSL) (29), hence decreasing lipolysis.  Similarly, 
gluconeogenesis is also inhibited by inactive PKA.  Inactive PKA does not phosphorylate 
and activate fructose 2,6-bisphosphatase (Fru-2,6P2ase) (30).  Inactive Fru-2,6P2ase can 
not catalyze conversion of fructose-2,6-biphosphate (Fru-2,6P2) into fructose-6-
phosphate (Fru-6P) (31). Hence, Fru-2,6P2 accumulates and inhibits fructose 1,6-
bisphosphatase (Fru-1,6P2ase) (32) - an enzyme that is involved in gluconeogenesis.
40 
 
1.3  MECHANISM OF ACTION OF INOSITOL GLYCANS 
 Several natural and synthetic IGs have been shown to mimic some of the actions 
of insulin.  As described above, insulin signaling is an entirely intracellular process.  The 
question arises as to how IGs, which are located on the extracellular face of the plasma 
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membrane, are able to trigger intracellular signaling events?  What kind of endocytosis 
mechanism is involved?   
A study by Alvarez et al in 1991 showed that IGs do get transported through the 
plasma membrane via an IG transporter.41  However, there is evidence that internalization 
is not necessary for the action of IGs.  A fluorescent synthetic IG analogue was found to 
stimulate lipogenesis in rat adipocytes despite the fact that it did not enter the cell.42  On 
the other hand, the ability of a natural IG to modulate the activity of purified pyruvate 
dehydrogenase (PDH) phosphatase in a cell free assay suggests an intracellular, as well as 
an intra-mitochondrial role.43  
 The mystery of the role of IGs as ‘second messengers of insulin action’ has been 
resolved, to some extent, through the enormous efforts of Muller and coworkers.38,44-46  
According to their findings, the insulin-signaling pathway is cross-linked downstream to 
an insulin receptor-independent insulin-mimetic signaling pathway via specialized lipid 
raft domains like DIGs and caveolae.47   DIGs and caveolae associate with signaling 
proteins like non-receptor tyrosine kinases (NRTKs), (dually) acylated small and 
heterotrimeric G proteins, and GPI-anchored proteins via lipid-lipid interactions.  
Depending upon their cholesterol to caveolin ratio, DIGs may be either hcDIGs (high in 
cholesterol and other signaling protein content and low buoyant density), or lcDIGs (low 
in cholesterol content and high buoyant density).  Signaling proteins are confined to 
hcDIGs via binding either to caveolin (for (dually) acylated proteins like NRTKs), or to a 
trypsin/NaCl/NEM sensitive polypeptide receptor, p115 (for GPI-proteins and 
phosphatidylinositolglycan peptides [PIG-P]).46   
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A cartoon representation of the mechanism of action of IGs is shown in figure 5.35  
Insulin stimulates a GPI-PLC (1) that lipolytically cleaves GPI-anchored proteins (and, 
perhaps free GPIs) on the outer leaflet of the cell membrane (2).  The lipolytically 
cleaved protein-IG conjugate (and IGs) (3), promotes GPI-anchored protein(s) to 
dissociate from the receptor and get translocated from hcDIGs to lcDIGs (4).  
Simultaneously NRTKs like pp59 (Lyn) are dissociated from caveolin and are 
redistributed between hcDIGs and lcDIGs (5).48  Activated kinase pp59 (Lyn) further 
activates another kinase, pp125 (Fak), (6) that is able to recruit IRS proteins (7) for 
phosphorylation by pp59 (Lyn) (8) at the sites that are recognized by PI-3 kinase.  This 
step triggers the phosphorylation cascade of insulin signaling pathway and acts as a point 
of convergence between the mechanism of action of IGs and insulin. 
 
 Figure 5. Mechanism of action of IGs on cell surface (Reproduced from Future Medicinal 
Chemistry (2009), 1(1), 95-118 with permission of Future Science Ltd). 
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1.4  SYNTHETIC IGs: A NEW GENERATION ANTI-DIABETIC AND/OR  
      ANTI-CANCER AGENTS  
 Although IGs appear to be promising candidates for second messengers of insulin 
action, the lack of information related to their exact chemical structure, and the difficulty 
in isolating these compounds in homogeneous forms, make it difficult to study their 
biological activities in detail.  An alternative to purification of natural IGs is to prepare 
pure IG analogues using organic synthetic chemistry.  The design of the first synthetic IG 
was based on the structure of  natural IPG 1 derived from the GPI anchor of the variant 
surface glycoprotein of T. brucei (Figure 3)1 which was shown to mimic the 
antigluconeogenic activity of insulin in rat hepatocytes.20  This synthetic IG analogue was 
an IPG-A type disaccharide [1D-6-O-(2-amino-2-deoxy-α-D-glucopyranosyl)-myo-
inositol 1,2-(cyclic phosphate)] with moderate insulin-mimetic activity (Figure 6, 
compound 3).49  The absence of charged groups (Figure 6, compound 4 and 5) or the 
presence of an acyclic phosphate group on the myo-inositol moiety was found to result in 
compounds that had no insulin-mimetic activities.49  This suggested that an insulin-
mimetic IG analogue must have at least an amino sugar and a cyclic 1, 2-phosphate group 
on myo-inositol.  The glucosamine moiety is also necessary for the insulin-mimetic 
activity.  An IG analogue with an amino group and cyclic 1, 2-phosphate, but lacking a 
glucosamine moiety, showed no insulin-mimetic activity.50 
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Based on the above analysis, several research groups have attempted to synthesize 
different analogues of IG compounds in order to understand their structure-activity 
relationship.49,51-57  The most extensive synthetic efforts have been reported from 
Muller’s laboratory.52  This group synthesized an array of 46 different IPG-A type IG 
analogues, some of which have potent insulin-mimetic activities.  It was concluded that 
the most important features that should be present in an insulin-mimetic IG are the 
following: a myo-inositol-1, 2-cyclic phosphate; an unacylated glucosamine; and some 
anionic groups on the distal mannose residues.  Some of the IG analogues with potent 
insulin-mimetic activity are shown in Figure 7.  The activity of structurally defined IGs 
has recently been reviewed.58 
Figure 6. Compound 3 is a synthetic IG disaccharide with modest insulin-mimetic 
activity; compounds 4 and 5 are IG disaccharides without charged functional groups and 
having no insulin-mimetic activity. 
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The structure activity relationship of these IGs also revealed that the number of 
mannose residues could be reduced, however, without adversely affecting the activity of 
the compound.  Thus compounds 10 and 11 with shorter oligosaccharide chains were 
found to be as effective as the hexasaccharides shown in Figure 7 (Figure 8).56 
Figure 7. Structures of some potent synthetic IGs.  
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Many researchers have also reported syntheses and biological activities of IPG-P 
type IGs (Figure 9).57,59  The structure-activity relationship of these synthetic IGs has not 
yet been completely explored, so it might be possible that the next generation of IGs 
could be based on such structures.  
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 Figure 9. Structures of synthetic IPG-P type IG analogues.  
Figure 8. Structures of IG analogues with fewer mannose residues, but with 
similar insulin-mimetic activity.  
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1.5  INOSITOL GLYCANS AND DIABETES 
As described before, the association of insulin with the IR triggers the insulin-
signaling pathway that controls the activity of several metabolic enzymes further 
downstream.  Failure to uptake and store nutrients due to a defect in the action of insulin 
results in diabetes, a disease associated with excess glucose in blood serum.  IGs act 
downstream of the IR and hence can trigger the insulin signaling pathway even if insulin 
is absent or if the insulin receptor is defective.25  Insulin-mimetic activities of IGs include 
stimulation of anabolic metabolism via increase in glycogen synthesis, glucose transport, 
and lipogenesis.  These activities suggest a possible role for IGs in the treatment of 
diseases, like type II diabetes, associated with insulin resistance in insulin sensitive cells.  
So the question arises: what is type II diabetes? 
 
1.5.1  Diabetes as a disease 
 Diabetes mellitus is a disease associated with high glucose concentration in blood 
and urine, a condition called hyperglycemia.  The major cause of diabetes is improper 
functioning or utilization of the hormone insulin by insulin sensitive cells.  Insulin 
regulates transportation of excess glucose into the cells and the overall blood glucose 
level in the body.  Insufficient production of insulin in the pancreas, or the inability of 
cells to use insulin properly and efficiently, leads to elevated levels of blood glucose or 
hyperglycemia.  Type I diabetes is a condition in which insulin is not produced in 
sufficient amounts by the pancreas.  Type II diabetes is a condition in which insulin is 
available in the blood stream but it cannot activate the insulin receptor and the insulin 
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signaling cascade sufficiently.  Type I diabetes can be treated by insulin injections and 
diabetic diet, but in type II diabetes the cells do not respond to the effects of insulin, a 
condition called “insulin resistance”.  Hence exogenously supplied insulin is useless for 
the treatment of type II diabetes.  The only resort for a type II diabetic patient is 
controlled diet, regular exercise, and lifelong medication in order to maintain the normal 
blood glucose level. 
 
1.5.2  Insulin resistance in type II diabetes 
 Insulin resistance is a condition in which the amount of insulin is insufficient to 
produce a normal response in insulin sensitive fat, liver and muscle cells.60  Insulin 
resistant cells are unable to perform their functions normally resulting in excess 
hydrolysis of triglycerides into fatty acids, excess production of glucose in liver, and 
decreased levels of glycogen in muscles.  All these factors contribute to the increase in 
blood glucose levels.  In response to the increased blood glucose concentration, the 
pancreatic beta-cells secrete more insulin.  Accumulation of high levels of both insulin 
and glucose in the blood is characteristic of type II diabetes.   
What causes insulin resistance?  Negative regulators of insulin signaling are 
responsible for terminating the insulin signal transduction pathway.  Insulin signaling can 
be terminated by any one of the following: internalization of the insulin-insulin receptor 
complex into endosomes and degradation of insulin by insulin degrading enzyme 
(IDE);61 mutation in Caveolin-1 gene that codes for caveolin, a caveolae localized 
protein38 that associates with IR; development of an excess of visceral adipocytes that are 
  19
relatively resistant to anti-lipolytic insulin signaling, and as a result, secrete a lot of non-
esterified fatty acids (NEFA) into the bloodstream.  NEFAs can block insulin signaling in 
other cells via several possible mechanisms or they can impair glucose metabolism in 
liver.62  
 
1.5.3  Treatment of type II diabetes 
 Type II diabetes has become an area of intense research and development due to 
the challenges associated with the disease.34  Therapeutic strategies for the treatment of 
type II diabetes involve stimulation of pancreatic beta cells (by stimulators like 
sulfonylureas), inhibition of glucose production in liver (by biguanides, etc.), inhibition 
of carbohydrate absorption in the intestine, stimulation of insulin sensitive cells to insulin 
(by insulin sensitizers like thiazolidinediones), and activation of insulin receptor by 
insulin receptor agonists or insulin mimetics.63  As described above, agents like IGs, 
unlike insulin, can trigger the insulin-signaling cascade without interacting with the 
insulin receptor.14  This feature makes IGs a possible therapeutic agent for type II 
diabetes.  Some synthetic IGs have been tested for their biological activities and have 
been shown to have potent insulin-mimetic activities.58  However, the use of IGs as anti-
diabetic drugs is limited by the fact that these compounds are highly complex and involve 
challenging synthetic strategies.   
 Synthetic efforts from Prof. Marc d’Alarcao’s laboratory have also contributed to 
the category of biologically active IGs.  Recently they have synthesized a simple acylated 
IPG: GlcN-(α 1-6)-myo-Ins-1-phosphate-2-palmitate (Figure 10) that has been tested for 
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its activity to inhibit lipogenesis.64  This acylated IPG was shown to inhibit lipogenesis in 
rat adipocytes to an extent similar to other potent insulin-mimetic IG analogues. 
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1.6  INOSITOL GLYCANS AND CANCER 
 Cancerous tumor cells switch to an alternate metabolic pathway (called aerobic 
glycolysis) to escape the natural phenomenon of apoptosis or programmed cell death 
(PCD) initiated in the mitochondria.  Insulin-mimetic IGs can stimulate aerobic 
metabolism in insulin-sensitive cells via stimulation of PDH phosphatase.65  Before 
understanding the potential of IGs to treat tumors, it is important to understand the 
cellular metabolism of cancer.   
 
1.6.1  Cancer as a disease 
 Cancer is a disease characterized by uncontrolled growth of abnormal cells due to 
certain defects (or mutations) in the process of normal cell division.  Normal cells obtain 
energy by oxidation of glucose and undergo a process of cell proliferation and growth for 
certain biological functions.  After performing their respective roles, cells become worn 
out and get disposed off via the process of apoptosis.  Cancer cells proliferate and grow 
unlimitedly, but in contrast to the normal cells they do not undergo apoptosis.  As a 
Figure 10. Structure of an acylated IPG analogue. 
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result, these cells develop into a mass of cellular components called a tumor.  If a tumor 
is confined to a tissue or an organ it is generally benign.  Such a tumor can be treated by 
surgery or radiation therapy.  However, if a tumor grows without limit, invades and 
damages the surrounding tissues, enters into the blood vessels, and spreads to other parts 
of the body (metastasis), it is called a malignant tumor.  Malignant tumors cause the 
major number of cancer deaths.  
  
1.6.2  Biochemistry of cancer growth 
 The major cause of invasive tumors is proposed to be an altered glucose 
metabolism.66  Glucose is the main source of energy (in the form of ATP) for all 
metabolic processes occurring in the body.  Under normal conditions glucose enters into 
the glycolytic pathway that converts glucose into pyruvate.  In aerobic metabolism, 
pyruvate enters the mitochondria where PDH phosphatase converts pyruvate into acetyl 
CoA, which is further consumed in the tricarboxylic acid (TCA) cycle, producing CO2, 
H2O and 36 ATP per glucose molecule.  Cancer cells limit the oxidative phosphorylation 
(though oxygen supply is available) and undergo an alternative metabolic process, 
aerobic glycolysis, whereby the glycolytic product, pyruvate, is reduced to lactic acid 
generating two molecules of ATP per glucose molecule (Figure 11).67,68  Consequently, 
cancer cells consume far more glucose than normal cells to maintain a sufficient ATP 
supply for their active metabolism and proliferation.   
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1.6.3  Enhanced aerobic glycolysis in cancer cells: The Warburg effect 
In 1930 Otto Warburg, a German scientist first observed the phenomenon of 
increased glycolysis in tumor cells under aerobic conditions.  He showed that, compared 
to normal cells, malignant cells exhibit significantly elevated glycolytic activity even in 
the presence of sufficient oxygen.  Warburg considered this phenomenon the most 
fundamental metabolic alteration in malignant transformation, or the origin of cancer 
cells.69  Later this phenomenon became known as the Warburg effect.  Increased uptake 
of glucose by cancer cells is evident from positron emission tomography (PET) studies 
Figure 11. Schematic representation of relationship between IG and the glucose 
metabolism. 
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using a glucose analogue tracer 18fluorodeoxyglucose (FdG).70  So the question arises: 
why do cancer cells alter their metabolic pathway?  What is the advantage of switching to 
aerobic glycolysis even in the presence of oxygen?  The answer to these questions is 
evident from understanding the role of mitochondria in glucose metabolism and control 
of cell growth. 
 
1.6.4  Mitochondria, apoptosis, and cancer 
Mitochondria are the major source of cellular energy in the form of ATP.  
Mitochondria also play an important role in the regulation of cellular metabolism and cell 
death.  Old and damaged cells undergo a process of well designed, controlled and 
regulated programmed cell death (PCD) or apoptosis whereby the damaged cells undergo 
a “clean” death and excretion from the body.71  Many pro-apoptotic proteins such as 
Apoptosis Inducing Factor (AIF), cytochrome c, etc., residing in the mitochondria, 
control this apoptotic process.  Any uncontrolled growth or division of cells is thus 
regulated in a programmed manner.  Due to uncontrolled proliferation, cancer cells 
should also undergo the process of apoptosis.  But cancer cells, due to the aerobic 
glycolysis, shift the metabolic burden away from mitochondria (Warburg effect).  Since 
cancer cells escape oxidative phosphorylation and switch to anaerobic metabolism, they 
are able to escape the process of apoptosis that is initiated in the mitochondria.     
                 
  24
1.6.5  Treatment of cancer via metabolism 
Several mechanisms have been suggested to affect energy metabolism of cancer 
cells that might contribute to the Warburg effect.71  These metabolic changes may occur 
due to a number of factors: mitochondrial defects such as mutation in mitochondrial 
DNA resulting in malfunctioning of oxidative phosphorylation;72 an adaptation to 
hypoxic environment in cancer tissues;67 activation of certain oncogenic signals like Akt, 
Bcl-2 etc;73,74 and changes in the function of mitochondrial enzymes, like fumarate and 
succinate dehydrogenase,68 or due to abnormal expression of  metabolic enzymes like 
hexokinase II in the voltage dependent anion channel (VDAC) of the outer mitochondrial 
membrane.75  Association of hexokinase II with the mitochondrial membrane results in 
decreased mitochondrial outer membrane permeabilization (or MOMP), a process that 
mediates intrinsic apoptosis as well as increased aerobic glycolysis.71  Several 
compounds target these mitochondrial proteins and membranes in order to induce 
apoptosis in cancer cells.73,76     
An alternative strategy is to target aerobic glycolysis in cancer cells.66,77  
Inhibition of the glycolytic pathway would deprive the cancer cells of glucose, the major 
source of their energy production, and hence prevent them from growing and 
proliferating.  However, normal cells, having functional mitochondria, could still survive 
inhibition of glycolysis via alternative energy sources like fatty acids and amino acids 
that can produce ATP by alternate pathways in the TCA cycle.66  Glycolytic inhibitors 
such as glucose analogues (2-deoxyglucose, mannoheptulose, and 5-thioglucose), 
hexokinase inhibitors (3-bromopyruvate, and lonidamine), PDH inhibitors (oxythiamine), 
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and lactate dehydrogenase inhibitors (oxalate, etc) have been shown to selectively kill 
cancer cells both in vitro and in vivo suggesting their potential as anticancer drugs.66  
However, use of these glycolytic inhibitors as anticancer drugs  is not yet proved to be an 
absolutely safe treatment for cancer.  Certain normal tissues like brain, retinae and testis 
rely on glucose as the main source of energy (evidence of alternative sources of energy 
like amino acids, fatty acids, etc, are not known for these tissues).  Thus, glycolytic 
inhibition may deprive these tissues of glucose, and thus result in significant toxicity.66  
Moreover, current glycolytic inhibitors have low potency, stability and safety profiles.  
Thus, there is a need for more effective and stable anticancer drugs. 
 
1.6.6  Inositol glycans and treatment of cancer 
Another strategy to control cancerous growth might be to stimulate aerobic 
metabolism in cancer cells and essentially reverse the Warburg effect.  Stimulation of 
aerobic metabolism in cancer cells would force the cancer cells to undergo normal 
glycolytic pathway and oxidative phosphorylation in mitochondria, resulting in the 
induction of intrinsic apoptosis.  Compounds like IGs can stimulate aerobic metabolism 
in insulin-sensitive cells by stimulating the enzyme PDH phosphatase.65  Similarly, these 
compounds may also stimulate aerobic metabolism in tumor cells, and consequently, 
reverse the Warburg effect (Figure 11).  Stimulation of aerobic metabolism in tumor cells 
should reduce the production of lactic acid, the end product of aerobic glycolysis, while 
maintaining a constant glucose level.  Preliminary proof of this hypothesis has been 
obtained by the fact that one synthetic IG analogue: GlcN-(α 1-6)-myo-Ins-2-palmitate, 
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called IG-1 (Figure 12), is able to stimulate aerobic metabolism in cultured tumor cells.35  
Currently, the cytotoxic effect of IGs has been demonstrated only in IG-1, but the ability 
of other synthetic IG analogues to exhibit similar anticancer properties cannot be ruled 
out.  Hence, exploration of the efficiency of IGs for the treatment of cancer is still in its 
initial stages. 
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1.7  DESIGN AND METABOLIC ACTIVITY OF SYNTHETIC ANTI-CANCER 
       IG, IG-1 
1.7.1  Design and chemical structure of IG-1 
 The chemical structure of IG-1 was designed on the basis of two factors.  First, 
disaccharides are simpler to synthesize compared to the other complicated structures like 
those shown in Figures 7 and 8.  Secondly, the presence of an acylated fatty acid chain on 
the C-2 position of the inositol ring was based on the fact that a similarly acylated inositol 
ring is also present in compound 19, the chemical structure of an intermediate of the GPI 
anchor of human erythrocyte acetylcholinesterase (AChE) (Figure 13).78  Acylation of 
inositol renders it resistant to the cleavage by PI-PLC, however, the action of GPI-PLD is 
known to hydrolyze such acylated GPI anchors, generating the “second messengers” or 
Figure 12. Structure of IG-1. 
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IPGs.19  The similarity between structures of IG-1 and 19 suggests that IG-1, like 19, 
may not be immunogenic. 
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1.7.2  Biological activity of IG-1 
 Synthesis of compound IG-1 was successfully accomplished in Marc d’Alarcao’s 
laboratory in 2007.35  The insulin-mimetic activity of IG-1 was confirmed by its ability to 
inhibit lipogenesis to an extent comparable to that of the simple disaccharide 3 (Figure 6).  
The reported activity of IG-1 was 24% MIR (maximal insulin response) with an EC50 
value of 14 µM.  In addition to being an insulin-mimetic, IG-1 was also reported to have 
cytotoxic effects on several human cultured cancer cell lines including cells from 
mammary cancer (MCF-7), pancreatic cancer (Panc-1, MiaPaca 2, and BXPC3), and 
gastric cancer (MKN4S).  At 100 µM concentration, the cytotoxic effects of IG-1 were 
Figure 13. Glycolipid intermediate formed during biosynthesis of GPI 
anchor of human erythrocyte AchE. 
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found to be comparable to compounds like resveratrol and butyrate, both known to 
induce apoptosis in cancer cells (Figure 14a).79  Furthermore, the cytotoxicity of IG-1 
was highly selective, in the sense that only cancer cells were killed, while the normal 
cells were completely unaffected by IG-1 (Figure 14b). 
 
 
Figure 14. (a) Effect of IG-1 on MCF-7 cancer cell line compared to another IG 
analogue, IG-2, resveratrol and butyrate (b) Cytotoxic effect of 100 µM IG-1 on normal 
(blue) and cancer cells (orange) (Data reproduced with permission of Prof. Marc 
d’Alarcao, San Jose State University). 
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                 These data suggest that IG-1 has the potential to be used as an anti-cancer 
drug, acting via an unknown mechanism that involves the stimulation of aerobic 
metabolism, and thus induction of apoptosis in cancer cells.  However, the utility of IG-1 
as an anticancer agent is limited due to the instability of the acyl group under 
physiological conditions as described below. 
 
1.7.3  Limitations of IG-1 
Compound IG-1 (Figure 12) is a disaccharide with a palmitoyl group attached at 
the C-2 position of the inositol ring.  The ester linkage, in general, is labile and readily 
hydrolysable.  Compounds with ester linkages can easily be hydrolyzed under acidic or 
basic conditions.  Esterases in the blood are also capable of hydrolyzing ester linkages 
under physiological conditions.  IG-1, with an ester linkage, is therefore susceptible to 
such hydrolysis in blood (Figure 15).  The hydrolyzed product 20 is reported to have no 
cytotoxic effects.   
Another major issue related to the stability of IG-1 is the migration of the 
palmitoyl chain to other hydroxyl groups.  IG-1, with a palmitoyl chain in the axial 
position, has the desired cytotoxicity but relatively low stability.  Migration of this 
palmitoyl chain to the more energetically preferable equatorial position (via a trans-
esterification reaction), results in stable compound 21, but is also accompanied by 
complete loss of activity (Figure 15).  Thus, either hydrolysis of the ester linkage or 
migration of the palmitoyl chain to other hydroxyl groups can result in loss of activity of 
IG-1.                                                      
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Any strategy that can prevent these drawbacks of IG-1 would be effective in 
synthesizing a potential anticancer IG.  One such strategy has been proposed by Prof.  
Marc d’Alarcao, and it forms the basis of my research project. 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Limitations of IG-1. 
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CHAPTER 2 
RESEARCH GOAL AND SYNTHETIC PLAN 
 
2.1  RESEARCH GOAL 
As discussed in Section 1.7.3 of Chapter 1, the major problem hypothesized with 
IG-1 that might restrict its use as an anticancer agent is related to its stability and 
migration of the palmitoyl chain to other hydroxyl groups under physiological conditions.  
Thus the current research goal is to synthesize an analogue of IG-1 that would have 
either an ether or thioether linkage between the fatty-acid chain and the myo-inositol.  
The hypothesis is that since ethers and thioethers are comparatively more resistant to 
hydrolysis than esters, replacement of the functional groups might induce extra stability 
in the compound, thus resulting in a greater half-life of the compound in the body.  
Consequently, two possible IG analogues, 22 and 23, have been designed that might be 
able to mimic the activities of IG-1, while maintaining their structural arrangement under 
physiological conditions (Figure 16).  
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Figure 16. Analogues of IG-1 with an ether (22) or thioether linkage (23) at C-2 
position of inositol ring. 
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2.2  SYNTHETIC STRATEGY 
2.2.1 Retrosynthetic analysis of analogues of IG-1, 22 and 23 
A retrosynthetic analysis for preparation of the desired analogues 22 and 23 is 
shown in Scheme 1.   
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Compounds 22 and 23 could be obtained by reduction of fully protected 29 and 
30, respectively.  The protective groups employed for these compounds are benzyl ether 
and azide groups for the protection of alcohol and amine functional groups, respectively.  
The advantage of using these protective groups is their easy deprotection.  Compound 29 
could in turn be obtained from 28  by Mitsunobu inversion at C-1 position of myo-
inositol ring.  Mitsunobu inversion has been widely used for inversion of stereochemistry 
of alcohols since 1967,80 particularly due to its advantage of mild reaction conditions and 
compatibility with a wide array of functional groups.  Compound 28 could be obtained 
regioselectively from 27 by nucleophilic trans-diaxial ring opening of epoxide.  Both 
Scheme 1. Retrosynthetic analysis of compounds 22 and 23. 
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acid-catalyzed and base-catalyzed ring opening of the epoxide is possible.  However, the 
acid-catalyzed ring opening reaction is more efficient due to the reversible formation of 
more reactive conjugate acid of the epoxide and also due to the solvation of the oxonium 
form of the epoxide in acidic solutions.81  The acid-catalyzed ring opening of 27 could 
however, be problematic due to the possibility of hydrolysis of the glycosidic linkage 
under acidic conditions.  Thus optimum conditions for acid catalyzed ring opening of 27 
need to be determined.  A diastereomeric mixture of two possible epoxides of 27 could in 
turn be obtained by epoxidation of olefin pseudodisaccharide 26 using either m-
chloroperoxybenzoic (mCPBA) or dimethyldioxirane (DMDO) solution in acetone.  
Olefin pseudodisaccharide 26 can be synthesized by α-selective glycosylation reaction of 
myo-inositol derivative 25 with fully protected 2-azido-2-deoxy-glycosyl bond donor 24 
under controlled conditions.35  Conduritol 25 could be synthesized from commercially 
available D-xylose 33 in 9 steps as shown in Scheme 2.53,82  The overall yield for these 
step reactions is about 16-20%.  However, the advantage of following this scheme is that 
the reactions could be performed on larger scales. 
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Alternatively, 29 could also be obtained from diol intermediate 32 by selective 
alkylation at the axial hydroxyl group (Scheme 1).35  In alkylation reactions of an axial-
Scheme 2. Synthesis of conduritol 25 from D-xylose. 
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equatorial pair of cis-diols, the equatorial oxygen would react preferentially.83,84  
However, benzylation of the equatorial hydroxyl group of 32 followed by an alkylation 
reaction with palmityl halide might yield 29 regioselectively.  Diol intermediate 32 is a 
known compound that could be prepared from olefin pseudodisaccharide 26 by the well-
known Sharpless asymmetric dihydroxylation reaction using catalytic amounts of 
osmium tetroxide and triethylenediamine (DABCO).35  The disadvantage of this pathway 
would be the difficulty in asymmetric dihydroxylation of cis-alkenes.85  However, the 
advantage would be a much shorter synthetic route to the target compound 22 as 
compared to the epoxidation pathway.     
The trichloroacetimidate donor 24 is also a known compound that could be 
synthesized from commercially available D-glucosamine 36 as shown in Scheme 3b.86,87  
An alternate strategy for synthesis of 24 was also proposed in Scheme 3a.  The advantage 
of scheme 3a would have been a novel synthetic route to 24.  Unfortunately, the proposed 
scheme did not work. 
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The synthetic scheme to 23 was based on the trans-diaxial ring opening of the 
epoxide 27 using the corresponding thiolate anion of commercially available 
hexadecanethiol (instead of the alkoxide anion of haxadecanol) as a nucleophile (Scheme 
1).  Thiolate anion would be a better nucleophile than alcohol owing to the larger size and 
lower electronegativity of sulfur as compared to oxygen.  So, there could be a better 
chance of successful nucleophilic substitution with the thiolate anion as opposed to the 
Scheme 3. Synthesis of trichloroacetimidate donor 24 from D-glucosamine. 
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alkoxide anion.  Also the thioethers are amenable to further oxidation resulting in the 
corresponding sulfoxides and sulfones.  A sulfoxide analogue of 23 would be structurally 
more analogous to IG-1 (similarity with the carbonyl group), and thus there could be a 
better chance for synthesizing a more stable compound than IG-1 with similar biological 
activities.  However, there are two possible diastereomers of the sulfoxide, complicating 
the synthesis. 
 
2.2.2  Regioselective monoalkylation of vicinal diols   
Monoalkylation of vicinal diols with alkyl halides typically results in the 
corresponding ethers.  The most general method for such O-alkylation of alcohols is the 
Williamson’s ether reaction that involves the treatment of an alkyl halide with alkoxide 
ion prepared from the corresponding alcohol in presence of a suitable base.  However, in 
carbohydrate polyols, attempts at selective alkylation of secondary hydroxyl groups 
(bearing similar reactivity) by a Williamson-type procedure would result in a mixture of 
ethers.  Thus selective protection of hydroxyl groups in carbohydrate diols or polyols is 
required. 
Use of organotin derivatives for regioselective acylation, alkylation and oxidation 
of alcohols has been extensively reviewed in the past.83  Treatment of vicinal diols (cis or 
trans) with dibutyltin oxide provides a cyclic “stannylene acetal” derivative (Scheme 4).  
The electropositive character of tin metal causes an increase in the reactivity 
(nucleophilicity) of an attached oxygen atom so that subsequent acylations or alkylations 
may be performed under mild conditions.  Moreover, due to a high degree of selectivity 
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for reaction at equatorial positions, this method is particularly useful for monoalkylation 
of equatorial hydroxy group in an equatorial-axial pair.88  Besides, the dibutyltin oxide 
method is able to selectively afford O-monosubstituted diol moieties even in the presence 
of other unprotected hydroxyl groups.89 
Scheme 4. Selective monoalkylation of vicinal diols. 
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Thus, based on the easy preparation of stannylene intermediates, their simple 
usage, and good yields and selectivity obtained, this method was chosen for the selective 
palmitylation of the cis-dihydroxylated compound 32.  
 
2.2.3  Epoxidation of olefin pseudodisaccharide 26 using mCPBA and (salen)-Mn 
          complexes  
 A literature search on epoxidation procedures revealed the use of catalytic 
amounts of chiral salen-based complexes for enantioselective epoxidation of olefins.90  
Oxidizing agents like mCPBA or bleach (NaOCl) are reported to be effective reagents for 
epoxidation, but they do not provide the desired selectivity.91  However, in the presence 
of co-oxidants such as N-methylmorpholine N-oxide (NMO) and Jacobsen’s catalyst  (N, 
N’-bis(3,5-di-ter-butylsalicylaldehyde)-1,2 cyclohexanediaminomanganese(III) chloride) 
(Figure 17), highly selective epoxidation products could be obtained. 
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Jacobsen’s catalyst is the most common salen-based complex used for 
stereoselective epoxidation of olefins.92  The likely mechanism of this catalytic reaction 
is illustrated in Scheme 5.  Initial transfer of the oxygen atom from the oxidant to (salen) 
Mn (III) results in a reactive (salen)-Mn (V) oxo intermediate that acts as an epoxidizing 
agent for the olefin.  Epoxidation proceeds via radical intermediate that can either form a 
C-O bond directly, or it may undergo rotation followed by C-O bond formation to give 
the two possible isomers of the epoxide.  However, in the case of cyclohexenes (as in our 
case) only the cis isomer is possible because of the high strain in a trans cyclohexene like 
structure. 
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Figure 17. Structure of R,R-Jacobsen’s catalyst. 
Scheme 5. Mechanism of (salen)-Mn complex catalyzed epoxidation. 
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The salen-based catalysts have chiral centers in the diamine bridge and chiral 
groups near the metal center, and, therefore, high catalytic activity and enantioselectivity 
could be obtained for a wide variety of olefins.  Enantioselection in the epoxidation of 
olefin is based on a side-on perpendicular approach of olefin to the Mn-oxo bond in the 
Mn (V) intermediate.90  Use of either of the commercially available isomers (R, R or S, 
S) may yield the desired epoxide in high enantiomeric excesses.91 
 
2.2.4  Alternative approach to synthesis of epoxide 27 using dimethyl dioxirane 
         (DMDO solution) 
Use of DMDO solution in acetone can also be employed for stereospecific 
epoxidation of alkenes.  DMDO is a powerful oxidizing agent that can be prepared as a 
solution in acetone from distillation of a buffered aqueous solution of potassium 
peroxomonosulfate or oxone (2KHSO5. KHSO4.K2SO4) in acetone.
93,94  DMDO is a 
volatile peroxide, and hence it is usually prepared as dilute solutions (0.4 to 0.15M) in 
acetone.  Being a strained cyclic peroxide, DMDO can readily transfer its peroxide 
oxygen to the alkene, thereby forming stable acetone as the only biproduct (Scheme 6).  
Thus advantages of using DMDO for epoxidation reaction are mild reaction conditions 
and easy work up.  Various computational models of the transition state show that the 
reaction occurs by a concerted mechanism similar to that with other peroxy acids.95  
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Scheme 6. Epoxidation of olefin pseudodisaccharide 26 using DMDO solution. 
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CHAPTER 3 
RESULTS AND DISCUSSION 
 
3.1  SYNTHESIS OF DIFFERENTIALLY PROTECTED MONOSACCHARIDE 
       UNITS 24 AND 25  
Synthesis of the target compounds 22 and 23 (Scheme 1, p. 32) was initiated by 
the syntheses of known compounds 24 and 25 via literature procedures (Section 
2.2.1).53,82,86,87  Initial attempts to synthesize 24 via Scheme 3a were unsuccessful 
probably due to the interconversion between the cyclic and acyclic forms of the 
glucosamine derivative (Figure 18).  Due to this interconversion, benzylation of 38 
resulted in a mixture of various benzylated products.  Scheme 3b, however, was 
successful, probably due to the higher stability of the phenyl thioglycoside group.86 
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3.2  COUPLING OF 25 WITH 24 
Following a previously known procedure, α-selective glycosylation of 25 with 24 
resulted in a 58% yield of olefin pseudodisaccharide 26 with a 3:1 ratio of the α and β 
anomers (Figure 19).35  
 
Figure 18. Interconversion between cyclic and acyclic forms of 38. 
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Chromatographic separation of the two anomers using a EtOAc/heptane solvent 
system (as reported in the literature)35 was not very efficient.  The spots for the starting 
material 24 and products were observed at the same Rf on TLC using this solvent system.  
However, much better separation was observed when the reaction progress was 
monitored by TLC using a 1:1 hexane: ether solvent system.  Also, careful observation 
revealed that the donor stained olive green, but the disaccharide product stained red in p-
anisaldehyde stain.  An amide side product 43 was also isolated from the reaction 
mixture.96  This impurity almost co-elutes with the β-anomer of the olefin 
pseudodisaccharide in the 1:1 hexane: ether solvent system.  However, the two can be 
separated efficiently using a 7:1 benzene: acetonitrile solvent system.  Another side 
product from this glycosylation reaction could be a homodimer of the 
trichloroacetimidate donor, 44 (Figure 20).  Use of old TfOH (may be wet), in one 
experiment, resulted in almost 80% conversion of the donor into homodimer 44 instead 
of it being converted into the desired disaccharide.  Thus for the most efficient 
glycosylation, it is absolutely necessary to use completely anhydrous reagents and dry 
conditions. 
Figure 19. Glycosydic coupling of the trichloroacetimidate donor 24 and the 
myo-inositol derived acceptor 25. 
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3.3  ATTEMPTED SYNTHESIS OF 27 VIA EPOXIDATION OF THE OLEFIN 
       PSEUDODISACCHARIDE 26 
 Before doing the epoxidation reaction on the quite precious disaccharides, 
practice epoxidation reactions were done on the model compounds styrene and 3-
cyclohexene-1-methanol using mCPBA, Jacobsen’s catalyst, and N-methylmorpholine-
N-oxide (NMO).  Both substrates provided the corresponding epoxides in decent yields 
(40-50%).  However, trial epoxidation on the beta-anomer of olefin pseudodisaccharide 
26β did not give the corresponding epoxide under any of those conditions (Table 1, 
entries 3-5).  There is the possibility of decomposition of the epoxide under acidic 
conditions, so the reaction was performed in buffered solutions.  But still there was no 
desired product obtained. 
 
 
 
 
  
Figure 20. Possible structure of the homodimer of trichloroacetimidate donor 24. 
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Table 1. Epoxidation reaction on different substrates under different conditions 
No. Substrate Conditions
a 
Yield % 
1. Styrene R,R catalyst (4 mol %), NMO (5 equiv), mCPBA 
(2 equiv), -78 ˚C91 
59 
2. 3-cyclohexene-
1-methanol 
R,R catalyst (5 mol %), NMO (5 equiv), mCPBA 
(2 equiv), 10% Na2CO3 solution, 0 ˚C
97 
40 
3. 26β R,R catalyst (4 mol %), NMO (5 equiv), mCPBA 
(2 equiv), -78 ˚C 
NRb 
4. 26β R,R / S,S catalyst (5 mol %), NMO (5 equiv), 
mCPBA (2 equiv), 0 ˚C 
NPc 
5. 26β R,R catalyst (5 mol %), NMO (5 equiv), mCPBA 
(2 equiv), 10% Na2CO3 solution, 0 ˚C 
NPc 
6.  3-cyclohexene-
1-methanol 
In situ reaction: Oxone (5 equiv), acetone (31 
equiv), Bu4NHSO4 (0.2 equiv), buffered water 
(pH 7.2), 2-4 ˚C, 30 min 
90 
7.  25 In situ reaction: Oxone (5 equiv), acetone (31 
equiv), Bu4NHSO4 (0.2 equiv), buffered water 
(pH 7.2), 2-4 ˚C, very slow reaction 
NPc 
8.  25 DMDO solution (large excess) NPc 
9. 26α DMDO solution (large excess) NPc 
 
Alternatively, the epoxidation reaction was also tried using freshly prepared 
DMDO solution in acetone.93,94  Assuming a low concentration of the DMDO solution, a 
large volume was used to ensure the addition of an excess of this solution.  The reaction 
a reference of literature procedure; b no reaction; c no product could be isolated due to decomposition   
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proceeded relatively quickly with model compound 3-cyclohexene-1-methanol under the 
reported conditions (Table 1, entry 6).94  We also tried to epoxidize conduritol acceptor 
25 under similar conditions.  However, with 25 the reaction proceeded very slowly 
(suggesting that the substrate might be sterically hindered).  Increasing the reaction time 
resulted in complete decomposition of the products.  An attempt was also made to 
epoxidize the alpha-anomer of the olefin pseudodisaccharide, 26α, using the higher 
concentration DMDO solution.  There was some trace of “product-like” compound 
formed during the initial few hours of the reaction, but soon there was complete 
decomposition of the product spot into several different compounds.  NMR spectra of all 
the compounds were taken, one of the spots could have been the desired product.  
However, considering the extent of decomposition observed in this reaction, and the 
limitation on the availability of the olefin pseudodisaccharide 26α, it was decided to wait 
on the epoxidation scheme and try the alternate approach via dihydroxylation. 
 
3.4  ATTEMPTED SYNTHESIS OF TARGET COMPOUND 22 VIA 
DIHYDROXYLATION OF 26 
After several unsuccessful attempts at epoxidation of 26, we decided to run the 
dihydroxylation reaction on 26α using the known procedure (Figure 21).35  Initially the 
reaction was started with the reported equivalents of the reagents.  However, the reaction 
proceeded very slowly, so it was pushed to completion at the expense of adding more 
reagents and increasing the reaction time.  The resulting cis-dihydroxylated product was a 
mixture of two isomers, 32 and 45, with the two OH groups “up” and “down” 
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respectively.  Careful separation using PTLC (45% EtOAc in heptane) yielded an almost 
1:1 ratio of the two isomers in a combined yield of 58%. 
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3.4.1  Identification and characterization of the two diols 32 and 45 
The next challenge was to identify the two dihydroxylated products.  NMR 
spectra of the two compounds were ambiguous for this purpose.  The identities of 32 and 
45 were established by running a palmitoylation reaction on one of the isomers, 45, 
Figure 22.  Comparing the NMR spectrum of the resulting product 46 to a known 
compound (90 in Azev’s thesis)35 confirmed the position of the hydroxyl groups in 45 to 
be “down”.35 
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Figure 21. Asymmetric dihydroxylation of pseudodisaccharide 26α. 
Figure 22. Palmitoylation of the diol 45. 
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Once identified, the desired diol 32 was subjected to selective monobenzylation 
via stannylene intermediate 48 (Figure 23).89  The two product isomers, 49 and 50, were 
isolated in a 4:1 ratio and 65% combined yield. 
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3.4.2  Identification and characterization of the two isomers 49 and 50 
Exact mass determination of the products by mass spectrometry indicated 
molecular formulae consistent with 49 and 50.  The next challenge was to identify which 
of the two isomers was the desired one (i.e. 49, the isomer with a benzyl group at the 1-
position and a free –OH group at 2-position of the myo-inositol ring).  Based on the fact 
that stannylene mediated alkylation is generally favored at the equatorial position, it was 
suspected that the major product was 49.  1H NMR and 2D COSY analysis of the minor 
isomer was used for further confirmation of this assumption.  If the minor isomer were 
assumed to be 50 (Figure 24), then Ins-H1 should be coupled with the –OH proton and its 
signal should be a ddd, which upon the removal of –OH coupling by deuterium exchange 
should change to a dd with a small and a large coupling constant.  The 1H NMR spectrum 
Figure 23. Selective monoalkylation of diol 32. 
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of the minor isomer was recorded first in deuterated DMSO (DMSO-d6) solvent, and then 
in DMSO-d6 with a drop of D2O.  The doublet at δ 5.22 ppm in the DMSO-d6 spectrum 
disappears on addition of D2O (Figure 25) indicating that this signal is due to the –OH 
hydrogen.  A 2D COSY spectrum of the minor isomer in DMSO-d6 was used to identify 
the proton that was coupled to the –OH group.  This proton could either be Ino-H1 (if 50) 
or Ino-H2 (if 49).  The signal for this proton was observed as a ddd at δ 3.71 ppm in 
DMSO-d6.  But, upon addition of D2O, the coupling between the –OH hydrogen and this 
proton disappeared and the multiplicity of the signal changed to a doublet of doublet with 
a small and a large coupling constant (Figure 25).  This indicated that the proton that is 
coupled to the –OH group in the minor isomer is Ino-H1, thus confirming our hypothesis 
that the minor isomer was actually 50. 
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Figure 24. Structures of compound 49 and 50 showing coupling with OH group. 
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3.4.3  Palmitylation of monobenzylated isomer 49 
The next step was to attach a palmityl chain to the free –OH group on the 2-
position of the myo-inositol ring of 49.  Cesium hydroxide based O-alkylation of alcohols 
was used as an initial approach.98  The advantage of using cesium bases over the other 
metal hydrides/hydroxides is their relatively high solubility in dipolar aprotic solvents 
like dimethyl formamide (DMF), appropriate basicity, and their high degree of 
dissociation into solvated cations and relatively “free” anions that are the reactive species 
for further nucleophilic substitution.99  The in situ generated cesium alkoxides are better 
nucleophiles that facilitate the SN2 type replacement.  The presence of added nucleophiles 
Figure 25. Deuterium exchange experiment with 50. 
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like tetrabutylammonium iodide (TBAI) and activated molecular sieves are known to 
accelerate nucleophilic substitutions considerably.  TBAI acts as a phase transfer catalyst 
and also provides a better leaving group (I-) for the electrophile.  Molecular sieves 
remove water from the reaction mixture thus preventing the protonation of alkoxides. 
 Before attempting the alkylation reaction on the most precious compound, 49, it 
was desirable to practice the cesium hydroxide-promoted alkylation on a model 
compound.  Alpha-methylbenzyl alcohol 51 was used for this purpose (Figure 26).  
Compound 51 was treated with the desired electrophile, palmityl bromide (C16H33Br), 
under slightly modified conditions from those described in the literature to give the 
corresponding ether 52.100  The reaction was very slow at room temperature.  Heating the 
reaction to 60 ˚C accelerated the rate of formation of the product.  However, the yield 
was moderate (20-30 %), possibly due to the E-2 elimination reaction in 51.  So this was 
not an ideal model for the practice of alkylation. 
  
OH C16H33Br, CsOH, TBAI, 
4Å MS, 60 °C, 36 h
OCH2C16H33
51 52   
 
 
 
 
Figure 26. Model palmitylation reaction. 
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3.4.4  Palmitylation of the monobenzylated product obtained from the undesired 
          (“down”) diol 
 Compound 45, being an isomer of 32, was subjected to the monobenzylation 
reaction via stannylene intermediate (Figure 27).  Only one isomer of the 
monobenzylated product could be isolated.  Repeated reactions have to be done to find 
out the details.  
O
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BnO
OBn
OBn
OBn
OH
OH
45
O
BnO
BnO
O
N3
BnO
OBn
OBn
OBn
OH OBn
53
O
BnO
BnO
O
N3
BnO
OBn
OBn
OBn
OBn OH
54
1) Bu2SnO, CH3OH:toluene (1:1), 
130 °C, 3h
2) Bu4NBr, BnBr, toluene, 
130 °C, 18 h
+
 
The resulting product, 53 with an axial –OH group on myo-inositol, was predicted 
to be a good model for practicing the alkylation reaction.  Both CsOH and NaH bases 
were tried under different experimental conditions, but unfortunately none of them gave 
the desired product (Figure 28). 
O
BnO
BnO
O
N3
BnO
OBn
OBn
OBn
OH OBn
53
NaH, C16H33Br, THF, ? h
O
BnO
BnO
O
N3
BnO
OBn
OBn
OBn
OC16H33
OBn
55
 
 
Figure 27. Selective monoalkylation of “undesired” diol 45. 
Figure 28. Practice alkylation on 53. 
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Interestingly, alkylation of 49 using NaH base and TBAI in THF solvent proved 
to be a successful trial (Figure 29).  High-resolution mass spectrometric analysis and the 
1H NMR spectrum of the resulting product proved its structure to be 29. 
 
O
BnO
BnO
O
N3
BnO
OBn
OBn
OBn
BnO
OH
49
O
BnO
BnO
O
N3
BnO
OBn
OBn
OBn
BnO
O(CH2)15CH3
29
NaH, TBAI, C16H33Br,
THF,  24h
 
 
Finally, deprotection of the fully benzylated 29 by dissolving metal reduction 
using the established procedure55 yielded the final lipid linked IG, 22, which was further 
desalted using a Sephadex® G-10 size exclusion column to afford pure 22 (Figure 30).   
O
BnO
BnO
O
N3
BnO
OBn
OBn
OBn
BnO
O(CH2)15CH3
29
O
HO
HO
O
NH3
HO
OH
OH
OH
HO
O(CH2)15CH3
22
1. Na, liq. NH3, -78 °C
2. NH4Cl(s), -78 °C
3. MeOH,  -78 °C
 
 
All of the reactions in the synthetic schemes were monitored by thin layer 
chromatography, and the products were characterized by 1H NMR spectroscopy.  Some 
products were further analyzed by high-resolution mass spectrometry. 
 
 
 
Figure 29. Palmitylation of 49. 
Figure 30. Deprotection of fully protected 29 
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CHAPTER 4 
CONCLUSIONS AND FUTURE GOALS 
 
Synthesis of a non-hydrolyzable, palmitylated inositol glycan has been partially 
accomplished.  Initial attempts to synthesize 22 and 23 via an epoxidation pathway 
(Scheme 1, p. 32) were not successful, probably due to the sterically hindered olefin 
pseudodisaccharide, 26.  However, an alternate pathway via dihydroxylation of 26 gave 
promising results.  The two dihydroxylated isomers 32 and 45 were successfully isolated 
(1:1 ratio) and characterized.  The position of the – OH groups (“up” or “down”) in the 
two isomers was determined by running a palmitoylation reaction on one of the isomers.  
The desired diol (with both –OH groups “up”) was successfully subjected to selective 
monobenzylation via a stannylene acetal intermediate.  The two isomers 49 and 50 were 
successfully isolated and characterized using 1H NMR and COSY analysis.  Palmitylation 
of 49 at the free hydroxyl group yielded fully protected lipid-linked disaccharide 29.  
Deprotection of the resulting product by reduction with sodium and liquid ammonia 
yielded the target compound 22. 
Future goals include optimization of the synthesis of 22, followed by biological 
testing for anti-cancer and anti-diabetic activities.  Another goal is to retry epoxidation of 
26 followed by the ring opening reaction.  Success of this reaction would enable the 
synthesis of 23, the thiol analogue of 22.       
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CHAPTER 5 
EXPERIMENTAL PROCEDURES 
 
General methods: Solvents and reagents obtained from commercial sources (Fisher 
Scientific or Sigma Aldrich) were used without further purification with the following 
exceptions: DMF, and pyridine were distilled under reduced pressure from barium oxide.  
Tetrahydrofuran (THF), toluene, and diethyl ether were distilled from sodium 
benzophenone ketyl.  Thiophenol was distilled using calcium chloride.  Acetic anhydride 
and methylene chloride were distilled at their boiling points.  Methanol was distilled 
using magnesium metal and iodine.  Compound 35 was provided by Prof. Marc 
d’Alarcao (work of his previous student).  All non-aqueous reactions were carried out 
under an argon or nitrogen atmosphere.  Organic extracts were dried with anhydrous 
Na2SO4 or MgSO4 and solvents were removed in vacuo on a rotary evaporator.  Rotary 
evaporation was accomplished at 10-15 Torr and 23 ˚C.  The carbohydrate intermediates 
were co-evaporated with toluene several times to make them completely anhydrous.  
Reactions were routinely monitored by thin layer chromatography (TLC) on Baker glass-
backed silica gel plates (0.25-mm thickness) with a 254-nm fluorescent indicator.  
Compounds were visualized by one or more of the following techniques: ultraviolet 
illumination; dipping the TLC plates in ethanolic solution of 2.5% p-anisaldehyde, 3.5% 
sulfuric acid, and 1% acetic acid followed by heating; dipping the TLC plates in ethanolic 
solution of Hanes-Isherwood stain (ammonium molybdate/HCl/perchloric acid/acetone); 
subjecting the TLC plates to iodine vapors.  Preparative separations were performed 
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either by flash chromatography on Baker silica gel (particle size 40-60 nm) or by 
preparative TLC.  Nuclear magnetic resonance (NMR) data for 1H were obtained on 
Inova-400 MHz or Inova-300 MHz NMR spectrometer and were reported in parts per 
million (δ) relative to TMS.  High-resolution mass spectrometry (HRMS) data were 
obtained using electrospray ionization mass spectrometer (ESI-MS) method at the 
Scripps Centre for Mass Spectrometry located in La Jolla, California. 
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O
HO
HO
NH2
OH
OH
O
AcO
AcO
N3
OAc
OAc
36
37
1. TfN3, H2O, CuSO4, Et3N, 23 °C
2. Ac2O, pyridine, DMAP, 23
 °C
 
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy- α/β-D-glucopyranoside (37).
101 (a) 
Preparation of TfN3: The reaction was set up under an argon atmosphere.  A solution of 
NaN3 (3.26 g, 0.05 mol) in dry acetonitrile (60 mL) was stirred vigorously at 0 ˚C for 10 
min.  Trifluoromethanesulfonic anhydride (7 mL, 6.67 x 10 –2 mol) was added slowly to 
the reaction mixture over 10 min.  The reaction mixture was stirred over an ice bath for 
about 2 h or until it turned milky white in color (the resulting TfN3 solution should not be 
evaporated as TfN3 is explosive when not in solution).
102  (b) Diazo-transfer: To a 
solution of D-glucosamine hydrochloride (11.05 g, 5.6 x 10 –2 mol) in water (55 mL) was 
added CuSO4 (140 mg, 5.6 x 10 
–4 mol) with vigorous stirring at 0 ˚C until a clear blue 
solution was formed.  After 15 min, distilled triethylamine (15.6 mL, 11.2 x 10 –2 mol) 
was added to the reaction mixture at 0 ˚C.  The color of the solution turned ink blue.  The 
triflic azide solution was then added to the glucosamine solution dropwise using a 
pressure equalizing dropping funnel.  The color of the solution turned yellowish brown.  
After 30 min, the ice bath was removed and the reaction mixture was allowed to stir at 
room temperature for 16 h.  The reaction mixture was then evaporated under vacuum to 
afford brown oil (Caution was exercised due to the explosive nature of TfN3).  The oil 
was coevaporated with toluene twice to remove any excess water.  (c) Acetylation: To a 
solution of the brown oil in pyridine (45 mL) at 0 ˚C was added DMAP (35 mg, 0.23 
mmol) and dry acetic anhydride (50 mL).  The mixture was stirred over an ice bath until 
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the reaction was no longer exothermic, and then stirred at room temperature until TLC 
(silica, 5% EtOAc in CH2Cl2) showed completion of the reaction, about 24 h.  The 
reaction mixture was then quenched with a saturated solution of NaHCO3, extracted with 
CH2Cl2 (4 x 250 mL), the combined organic phases were dried over MgSO4, filtered and 
concentrated in vacuo.  The crude product from the reaction was purified by flash 
chromatography (2% EtOAc in CH2Cl2) yielding 37 (8.5 g, 40%) as light brown oil.  Rf = 
0.17 (2% EtOAc in CH2Cl2).  
1H NMR (400 MHz, CDCl3): δ 2.02 (s, 3H, CH3CO), 2.07 
(s, 3H, CH3CO), 2.09 (s, 3H, CH3CO), 2.18 (s, 3H, CH3CO), 3.66 (m, 1H, H-7), 3.79 
(ddd, J = 1.2, 2.8, 4.8, 1H, H-5), 4.07 (dd, J = 2.1, 12.8, 1H, H-6), 4.29 (dd, J = 4.4, 12.8, 
1H, H-2), 5.12-4.99 (m, 2H, H-3, H-4), 5.54 (d, J = 8.8,1H, H-1).  Data is consistent with 
the literature values.102 
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37
41
BF3.Et2O, PhSH, CH2Cl2, 
23°C, 8 days
 
Phenyl-2-azido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-α/β-D-glucopyranoside (41).
86
  To a 
solution of 37 (1.9 g, 5.1 mmol) in CH2Cl2 (41 mL) was added freshly distilled 
thiophenol (1.05 mL, 10.28 mmol) followed by boron-trifluoride etherate (2.85 mL, 
23.12 mmol) with constant stirring under an argon atmosphere.  The reaction mixture was 
stirred at room temperature until TLC (5% EtOAc in CH2Cl2) showed almost 98% 
conversion of the starting material into the product, approximately 8 days.  The color of 
the reaction mixture changed from pale yellow to red to dark red as the reaction 
proceeded.  The reaction mixture was diluted with CH2Cl2 (100 mL) and washed with 
brine (8 x 50 mL).  The organic layer was dried over MgSO4, filtered and concentrated in 
vacuo to afford a light brown oil.  Purification of crude reaction product by flash 
chromatography (2% EtOAc in CH2Cl2) yielded 41 (1.13g, 52%) as a 3:1 α/β mixture (Rf 
of the mixture = 0.62 (5% EtOAc in CH2Cl2)).  Unreacted 37 (0.3g, 16% yield) was also 
recovered (Rf = 0.43 (5% EtOAc in CH2Cl2)).  
1H NMR for 41α (400 MHz, CDCl3): δ 
2.02 (s, 3H, CH3CO), 2.05 (s, 3H, CH3CO), 2.11 (s, 3H, CH3CO), 4.02 (dd, J6a,6b = 12.0, 
J6a,5 = 2.0, 1H, H-6a), 4.08 (dd, J = 10.8, 5.6, 1H, H-2), 4.29 (dd, J6a,6b = 12.0, J6b,5 = 5.4, 
1H, H-6b), 4.59 (ddd, J = 7.2, 4.8, 2.0, 1H, H-5), 5.02 (Ψt, J = 12.8, 12.0, 1H, H-4), 5.33 
(dd, J = 10.4, 9.2, 1H, H-3), 5.64 (d, J = 5.6, 1H, H-1), 7.26-7.51 (m, 5H, ArH).  1H 
NMR for 41β (400 MHz, CDCl3): δ 1.99 (s, 3H, CH3CO), 2.02 (s, 3H, CH3CO), 2.07 (s, 
3H, CH3CO), 3.39 (Ψt, J = 9.8 Hz, 1H, H-2), 3.68 (ddd, J = 9.8, 4.7, 2.3 Hz, 1H, H-5), 
  60
4.16 (dd, J6a,6b = 12.1, J6a,5 = 2.6, 1H, H-6a), 4.21 (dd, J6a,6b = 12.4, J6b,5 = 4.9, 1H, H-6b), 
4.48 (d, J = 10.2 Hz, 1H, H-1), 4.91 (Ψt, J = 9.64 Hz, 1H, H-4), 5.06 (dd, J = 9.6, 9.6, 
1H, H-3), 7.20-7.63 (m, 5H, ArH).   
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O
AcO
AcO
N3
OAc
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O
BnO
BnO
N3
OBn
SPh
42
1. aq. NaOH, nBu4NHSO4, 
benzene
2. BnBr, 23 °C, 24h
 
Phenyl-2-azido-3,4,6-tri-O-benzyl-2-deoxy-1-thio-α/β-D-glucopyranoside (42).
87
  To a 
pale yellow solution of 41 (1.13g, 2.62 mmol) in benzene (50 mL) was added 20% 
aqueous NaOH (25 mL) followed by tetra-n-butylammonium bisulfate (nBu4NHSO4, 
0.48 g, 1.52 mmol).  The heterogeneous mixture was stirred vigorously under argon 
atmosphere at room temperature (23 ˚C) for 1h.  Then BnBr (1.5 mL, 12.5 mmol) was 
transferred slowly into the reaction mixture over a period of 10 min.  The reaction 
mixture was stirred at room temperature until TLC (2% EtOAc in CH2Cl2) showed 
complete disappearance of the starting material, approximately 24h.  The reaction 
mixture was quenched with distilled water (160 mL) and diluted with toluene (400 mL).  
The organic layer was separated, washed successively with H2O (80 mL), 1M HCl (2 x 
80 mL), and H2O (2 x 80 mL), dried over MgSO4, filtered and concentrated in vacuo.  
Purification of the crude reaction product (a few drops of DMF were added to dissolve 
the crude product) by flash chromatography (9:1 hexane:EtOAc, Rf = 0.3) yielded a 
mixture of the two isomers of 42 (1.3 g, 87% yield).  Rf of the mixture = 0.8 (2% EtOAc 
in CH2Cl2).  
1H NMR for 42α (400 MHz, CDCl3): δ 3.63 (dd, J = 2.0, 10.8 Hz, 1H, H-
6a), 3.75 (Ψt, J = 8.9, 9.6 Hz, 1H, H-3), 3.81 (dd, J = 3.8, 7.7 Hz, 1H, H-2), 3.82 (Ψt, J = 
8.8, 9.8 Hz, 1H, H-4), 3.95 (dd, J = 10.0, 5.4 Hz, 1H, H-6b), 4.36 (ddd, J = 2.1, 3.6, 7.9 
Hz, 1H, H-5), 4.44 (d, J = 11.8 Hz, 1H, PhCH2O), 4.53 (d, J = 10.8 Hz, 1H, PhCH2O), 
4.60 (d, J = 11.8 Hz, 1H, PhCH2O), 4.81 (d, J = 10.9 Hz, 1H, PhCH2O), 4.87 (d, J = 10.6 
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Hz, 1H, PhCH2O), 4.92 (d, J = 10.8 Hz, 1H, PhCH2O), 5.61 (d, J = 5.4 Hz, 1H, H-1), 
7.14-7.52 (m, 30H, PhCH2O (20H) + CHCl3).  
1H NMR for 42β (400 MHz, CDCl3): δ 
3.34 (Ψt, J = 9.2, 9.3 Hz, 1H, H-2), 3.47 (m, 1H, H-5), 3.51 (Ψt, J = 9.2, 9.0 Hz, 1H, H-
3), 3.56-3.64 (m, 2H, H-4, H-6a), 3.76 (dd, J = 3.6, 8.8 Hz, 1H, H-6b), 4.38-4.46 (m, 1H, 
PhCH2O), 4.52-4.66 (m, 3H, PhCH2O), 4.76 (d, J = 9.6 Hz, 1H, H-1), 4.82-4.88 (m, 2H, 
PhCH2O), 7.14-7.62 (m, PhCH2O (20H) + CHCl3).            
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42 40
aq. acetone, NBS, -15 °C, 2h
 
 
2-Azido-3,4,6-tri-O-benzyl-2-deoxy-α/β-D-glucopyranose (40).
87  To a solution 
of 42 (1.77 g, 3.08 mmol) in acetone/water (99:1, 170 mL) under an argon atmosphere 
was added N-bromosuccinimide (NBS, 0.90 g, 5.08 mmol) with vigorous stirring at –15 
˚C (using a cold bath of 30% methanol in water and dry ice).  Reaction flask was covered 
with an aluminum foil to avoid light.  The color change from yellow to orange was 
observed as the reaction proceeded.  Progress of the reaction was monitored by TLC (3:1 
hexane: EtOAc) until all the starting material had  reacted, approximately 2h.  The 
reaction mixture was quenched with a saturated solution of NaHCO3 (250 mL).  The 
aqueous phase was extracted with EtOAc (4 x 100 mL).  The combined organic layers 
were washed with brine (2 x 100 mL), dried over MgSO4, filtered and concentrated in 
vacuo.  Purification of the crude reaction product by flash chromatography (3:1 
hexane:EtOAc, Rf = 0.28) yielded 40 as a white shiny powder (1.15g, 77%).  Rf = 0.28 
(3:1 hexane:EtOAc).  1H NMR for mixture of 40α and 40β (300 MHz, CDCl3): δ 3.24 
(dd, 1H, J = 1.9, 4.6 Hz, α -OH), 3.37 (dd, J = 10.1, 12.4 Hz, 1H, β-H-2), 3.40-3.47 (m, 
3H, α-H-2, α-H-6a, β-H-3), 3.49 (m, 1H, β-H-5 ), 3.52-3.72 (m, 5H, α-H-4, α-H-6b, β-
H-4, β-H-6a, β-H-6b), 3.76 (d, J = 7.4 Hz, β-OH), 4.02 (dd, 1H, J = 11.7, 13.4 Hz, α-H-
3), 4.08 (m, 1H, α-H-5), 4.44-4.64 (m, 7H, β-H-1 (1H), PhCH2O (6H)), 4.74-4.95 (m, 
6H, PhCH2O), 5.32 (dd, J = 4.8, 4.76 Hz, α-H-1), 7.09-7.44 (m, 33H, PhCH2O (30H) + 
CHCl3). 
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2-Azido-3,4,6-tri-O-benzyl-2-deoxy-α/β-D-glucopyranosyl trichloroacetimidate 
(24).
103
  To a solution of 40 (97 mg, 0.21 mmol) in dry CH2Cl2 (1.6 mL) under an argon 
atmosphere was added flame dried K2CO3 (0.14 g, 1.05 mmol) and trichloroacetonitrile 
(CCl3CN, 0.17 mL, 1.68 mmol).  The reaction mixture was stirred vigorously at room 
temperature and monitored by TLC (3:1 hexane:EtOAc) until the product formation was 
completed, about 4-12h.  2-D TLC proved some decomposition of the product on silica 
gel.  Complete disappearance of the starting material was not achieved.  The reaction 
mixture was filtered through a bed of silica gel over Celite using excess CH2Cl2 and 
evaporated under vacuum to yield a crude reaction product 24 (88 mg, 67%).  Rf of 
mixture = 0.46 (3:1 hexane:EtOAc).  Integrals from the 1H NMR of this mixture showed 
9:1 α/β ratio.  1H NMR for 24 β (400 MHz, CDCl3): δ 3.55 (Ψt, J = 9.2, 9.5 Hz, 1H, H-
2), 3.59 (m, 1H, H-5), 3.69 (m, 1H, H-6a), 3.73-3.80 (m, 3H, H-3, H-4, H-6b), 4.53 (d, J 
= 12.16, 1H, PhCH2O), 4.59 (d, J = 8.12, 1H, PhCH2O), 4.62 (d, J = 9.6, 1H, PhCH2O), 
4.81 (d, J = 10.88, 1H, PhCH2O), 4.85 (d, J = 10.92, 1H, PhCH2O), 4.90 (d, J = 10.97, 
1H, PhCH2O), 5.62 (d, J = 8.52, 1H, H-1 ), 7.12-7.44 (m, 20H, PhCH2O (15H) + 
CHCl3), 8.73 (s, 1H, NH).  Data is consistent with the literature.
103     
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OH
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OBn
BnO
OH
BnO
25
(Cy3P)2RuCl2(CHPh), 
CH2Cl2, 23°C, 45 min
35.1
OBn
BnO
OTIPS
BnO
TBAF, THF, 23°C, 1 h
35  
(a) 3(S)-Hydroxy-4(S),5(R),6(S)-tribenzyloxy-1,7-octadiene (35.1).
104  To a solution of 
compound 35 (114.7 mg, 0.192 mmol) in THF (1.4 mL) was added t-butyl ammonium 
fluoride (TBAF, 0.92 mL, 0.912 mmol) at 0 ˚C under an atmosphere of argon.  The 
reaction mixture turns pale yellow and then golden yellow in color.  After 10 min the 
reaction mixture was warmed to room temperature.  The progress of the reaction was 
monitored by TLC (6:1 hexane:EtOAc) until the completion of the reaction, about 1 h.  
The reaction mixture was evaporated under reduced pressure to give an orange-brown 
residue.  Purification of the crude reaction product by flash chromatography (6:1 
hexane:EtOAc) yielded pure 35.1 (94 mg, 80%).  Rf = 0.25 (6:1 hexane:EtOAc).   
1H 
NMR (400 MHz, CDCl3) δ 2.63 (d, J = 7.4, 1H), 3.74 (m, 2H), 4.10 (m, 2H), 4.36 (d, J = 
11.9, 1H), 4.77-4.61 (m, 5H), 5.37-5.14 (m, 4H), 6.02-5.82 (m, 2H), 7.32-7.25 (m, 16H, 
PhCH2O + CHCl3).  Data is consistent with the literature.
104   
(b) 3(S),4(R),5(R)-Tribenzyloxy-6(S)-hydroxycyclohexene (25).82  To a solution of 
compound 35.1 (94 mg, 0.21 mmol) in CH2Cl2 (10.0 mL) was added the first generation 
Grubb’s catalyst, (Cy3P)2RuCl2(CHPh), (17.12 mg, 20.75 µmol) at room temperature 
under an atmosphere of argon.  The color of the reaction mixture turned pink and then 
brown.  The reaction was monitored by TLC (7:3 hexane:EtOAc) until all the starting 
material was reacted, about 45 min.  Then the reaction mixture was opened to the 
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atmosphere for 4 h.  Thereafter, the reaction mixture was evaporated under reduced 
pressure to give a crude residue.  The residue was further purified by flash 
chromatography (7:3 hexane:EtOAc) to yield pure compound 25 (52 mg, 60%).  For 25: 
Rf = 0.32 (7:3 hexane:EtOAc); 
1H NMR (400 MHz, CDCl3) δ 2.13 (m, 1H), 3.52 (dd, J = 
8.0, 10.1, 1H), 3.78 (dd, J = 7.4, 10.2, 1H), 4.34-4.23 (m, 2H), 4.75-4.66 (m, 2H), 4.94-
4.87 (m, 2H), 5.02 (d, J = 11.4, 1H), 5.70 (m, 2H), 7.19-7.45 (m, 15H, PhCH2O).  Data is 
consistent with the literature.82 
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2-Azido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranosyl-α/β-(1 → 6)-3,4,5-tri-O-
benzyl-1,2-didehydro-1,2-dideoxy-D-myo-inositol (26α/β) and N-(2-azido-3,4,6-tri-O-
benzyl-1,2-dideoxy- α/β-D-glucopyranosyl) trichloroacetamide (43).
35
  Mixture of 
donor 24 (216 mg, 0.34 mmol) and acceptor 25 (156 mg, 0.37 mmol) were coevaporated 
three times with toluene to remove any traces of water.  Anhydrous ether (14 mL) and 
crushed activated molecular seives (4 Å, 230 mg) were added to the reaction mixture 
under an atmosphere of argon.  After stirring for 15 min the reaction mixture was cooled 
to -5 ˚C and a TfOH solution in ether (0.0626 M*, 0.51 mL, 0.1 equiv) was added 
dropwise.  The reaction mixture was stirred at -5 ˚C until TLC (1:1 hexane: ether) 
showed almost complete disappearance of the starting materials, about 1 h.  The reaction 
mixture was warmed to room temperature, quenched with solid NaHCO3 (230 mg), 
stirred for about 15 minutes, and then filtered into a separatory funnel.  The filtrate was 
washed successively with cold 5% aq. Na2CO3 (3 x 8 mL), water (2 x 8 mL) and then 
with brine (2 x 8 mL).  The ether layer was separated, dried over Mg2SO4, filtered, and 
evaporated under reduced pressure.  The crude residue was purified by flash 
chromatography (4:1 → 2:5 → 1:1 v/v hexane:ether) yielding most of the fractions with 
pure coupling products along with some impure fractions.  The impure fractions were 
combined and purified further by PTLC (1:1 v/v hexane:ether).  
* 0.0626 M TfOH solution was prepared by dissolving 56 µL of pure TfOH (11.3 M) in 10 mL of 
anhydrous ether.  
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All the pure fractions were combined separately yielding 140 mg of 26α (Rf =0.48 in 1:1 
v/v hexane:ether) and 40 mg of 26β (Rf =0.62 in 1:1 v/v hexane:ether) with a combined 
yield of 58%.  For 26α: Rf =0.51 (3:1 hexane:EtOAc); 
1H NMR (400 MHz, CDCl3) δ 
3.34 (dd, J = 10.9, 1.9 Hz, 1H, GluN-H-6a), 3.4 (dd, J = 11.1, 2.7 Hz, 1H, GluN-H-6b), 
3.45 (dd, J = 10.5, 3.5 Hz, 1H, GluN-H-2), 3.65-3.79 (m, 3H, GluN-H-4, Ino-H (2H)), 
3.96 (dd, J = 10.1, 9.1 Hz, 1H, GluN-H-3), 4.02 (ddd, 1H, GluN-H-5), 4.25 (m, 1H, Ino-
H), 4.29 (d, J = 11.9 Hz, 1H, PhCH2O), 4.4 (m, 1H, Ino-H), 4.45 (d, J = 11.1 Hz, 1H, 
PhCH2O), 4.54 (d, J = 12 Hz, 1H, PhCH2O), 4.65-4.74 (m, 3H, PhCH2O), 4.77 (d, J = 
11.1 Hz, 1H, PhCH2O), 4.83-4.99 (m, 5H, PhCH2O), 5.1 (d, J = 3.6 Hz, 1H, GluN-H-1), 
5.7-5.83 (m, 2H, Ino-H (2H)), 7.05-7.39 (m, 36H, PhCH2O (30H) + CHCl3).  For 26β: Rf 
=0.56 (3:1 hexane:EtOAc), Rf =0.71 (7:1 benzene:acetonitrile); 
1H NMR (400 MHz, 
CDCl3) δ 3.32-3.49 (m, 3H, GluN-H-2, GluN-H-3, GluN-H-5), 3.61-3.84 (m, 5H, GluN-
H-4, GluN-H-6a, GluN-H-6b, Ino-H (2H)), 4.26 (m, 1H, Ino-H), 4.46 (m, 1H, Ino-H), 
4.48-4.62 (m, 3H, PhCH2O), 4.65 (d, J = 7.6 Hz, 1H, GluN-H-1), 4.67-4.75 (m, 2H, 
PhCH2O), 4.77-4.93 (m, 6H, PhCH2O), 4.97 (d, J = 10.16 Hz, 1H, PhCH2O), 5.68-5.83 
(m, 2H, Ino-H (2H)), 7.15-7.21 (m, 2H, PhCH2O), 7.21-7.49 (m, 28.8H, PhCH2O (28H) 
+ CHCl3).  For 43: Rf =0.57 (3:1 hexane:EtOAc), Rf =0.66 (7:1 benzene:acetonitrile); 
1H 
NMR (400 MHz, CDCl3) δ 3.57-3.73 (m, 3H, H-3, H-5, H-6a), 3.78-3.94 (m, 3H, H-6b, 
H-4, H-2), 4.49 (d, J = 11.94 Hz, 1H, PhCH2O), 4.58 (d, J = 10.63 Hz, 1H, PhCH2O), 
4.64 (d, J = 11.95 Hz, 1H, PhCH2O), 4.77 (d, J = 10.62 Hz, 1H, PhCH2O), 4.85 (d, J = 
10.66 Hz, 1H, PhCH2O), 4.92 (d, J = 10.67 Hz, 1H, PhCH2O), 5.66 (dd, J = 6.55, 5.37 
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Hz, 1H, H-1), 7.00 (d, J = 6.48 Hz, 1H, NH), 7.1-7.2 (m, 2H, PhCH2O), 7.2-7.4 (m, 23H, 
PhCH2O (13H) + CHCl3).  Data is consistent with the literature.
35  
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2-Azido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranosyl-(1 → 6)-3,4,5-tri-O-benzyl-D-
myo inositol (32 and 45).
35
  To a solution of 26α (36.2 mg, 41.4 µmol) in THF (0.57 mL) 
and tBuOH (0.65 mL) was added water (408 µL) followed by K3[Fe(CN)6] (40.8 mg, 
124.2 µmol, 3 equiv), K2CO3 (124 µL of 1 M aq solution, 124.2 µmol, 3 equiv), DABCO 
(139 µL of 0.089 M aq solution, 12.42 µmol, 0.3 equiv), OsO4 (72.64 µL of 0.056 M aq 
solution, 4.1 µmol, 0.1 equiv), and MeSO2NH2 (7.79 mg, 82.8 µmol in 4.5 mL of H2O, 2 
equiv) at vigorous stirring under an argon atmosphere at 23 ˚C.  The reaction was 
monitored by TLC (45 % EtOAc in heptane, for 26α Rf =0.73, for 32 and 45 Rf =0.25-
0.35).  After 24 h 40-50 % conversion of the starting material was observed.  Addition of 
another batch of the reagents in the same proportion, however, pushed the formation of 
the osmate ester to completion, additional 24 h.  NaOH (63 µL of 1 M aq solution) was 
added followed by an additional stirring for about 12 h.  The reaction mixture was 
quenched by addition of solid Na2SO3 (100 mg).  The upper organic phase changed from 
yellow to colorless and the lower aqueous phase turned black.*  After stirring for 
additional 15 min the organic layer was separated.  The aqueous layer was extracted with 
toluene (3 x 1 mL) and the combined organic layers were washed successively with 1 M 
NaOH (2 x 1 mL), water (2 x 1 mL), 1 M Na2S2O3 (3 x 1 mL), water (1 x 1 mL), and 
brine (2 x 1 mL).  
* This color change was not observed in some cases.  
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The organic phase was dried over MgSO4, filtered, and evaporated to give a crude 
mixture of two diols 32 and 45.  The two diols had a very close Rf and were separated by 
PTLC (45 % EtOAc in heptane, 10-15 mg maximum loading) yielding 10.6 mg of pure 
32 and 10.8 mg of pure 45 with a combined yield of 58%.  For 32: Rf = 0.29 (45 % 
EtOAc in heptane); 1H NMR (400 MHz, CDCl3) δ 2.49 (m, 1H, OH), 3.03 (dd, J = 11.0, 
1.6 Hz, 1H, GluN-H-6a), 3.27 (dd, J = 11.0, 2.4 Hz, 1H, GluN-H-6b), 3.36 (Ψt, J = 9.7 
Hz, 1H, Ino-H-4), 3.47 (dd, J = 9.6, 2.7 Hz, 1H, Ino-H-3), 3.55 (dd, J = 10.1, 3.6 Hz, 1H, 
GluN-H-2), 3.57-3.62  (m, 1H, Ino-H-1), 3.69-3.83 (m, 2H, GluN-H-4, OH), 3.84-4.05 
(m, 4H, GluN-H-3, GluN-H-5, Ino-H-5, Ino-H-6), 4.11 (d, J = 12.5 Hz, 1H, PhCH2O), 
4.18 (m, 1H, Ino-H-2), 4.41 (d, J = 10.6 Hz, 1H, PhCH2O), 4.43 (d, J = 12.0 Hz, 1H, 
PhCH2O), 4.65 (d, J = 11.2 Hz, 1H, PhCH2O), 4.68-4.81 (m, 4H, PhCH2O), 4.86 (d, J = 
12.0 Hz, 1H, PhCH2O), 4.83 (d, J = 10.9 Hz, 1H, PhCH2O), 4.91 (d, J = 10.6 Hz, 1H, 
PhCH2O), 5.00 (d, J = 10.9 Hz, 1H, PhCH2O), 5.35 (d, J = 3.18 Hz, 1H, GluN-H-1), 
7.01-7.46 (m, 36.8H, PhCH2O (30H) + CHCl3).  For 45: Rf = 0.25 (45 % EtOAc in 
heptane); 1H NMR (400 MHz, CDCl3) δ 2.47 (m, 1H, OH), 3.05 (m, 1H, OH), 3.31 (dd, J 
= 10.9, 1.55 Hz, 1H, GluN-H-6a), 3.39 (dd, J = 11.1, 2.7 Hz, 1H, GluN-H-6b), 3.48 (Ψt, 
J = 9.28 Hz, 1H, Ino-H-4), 3.51 (dd, J = 9.6, 2.9 Hz, 1H, Ino-H-6), 3.58 (dd, J = 10.1, 3.6 
Hz, 1H, GluN-H-2), 3.65 (dd, J = 9.7, 2.7 Hz, 1H, Ino-H-2), 3.74 (Ψt, J = 9.6 Hz, 1H, 
GluN-H-4), 3.86 (Ψt, J = 9.76, 9.68 Hz, 1H, Ino-H-3), 3.87-4.00 (m, 3H, GluN-H-3, 
GluN-H-5, Ino-H-5), 4.22 (Ψt, J = 2.8, 2.6 Hz, 1H, Ino-H-1), 4.29 (d, J = 12.1 Hz, 1H, 
PhCH2O), 4.46 (d, J = 11.0 Hz, 1H, PhCH2O), 4.51 (d, J = 12.1 Hz, 1H, PhCH2O), 4.70 
(d, J = 10.7 Hz, 1H, PhCH2O), 4.76 (d, J = 11.0 Hz, 1H, PhCH2O), 4.80 (d, J = 11.1 Hz, 
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1H, PhCH2O), 4.83-4.91 (m, 4H, PhCH2O), 4.90 (d, J = 10.6 Hz, 1H, PhCH2O), 4.92 (d, 
J = 10.9 Hz, 1H, PhCH2O), 4.99 (d, J = 3.7, 1H, GluN-H-1), 7.01-7.49 (m, 35H, 
PhCH2O (30H) + CHCl3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  84
 
  85
 
  86
 
 
 
  87
 
  88
 
  89
 
 
  90
O
BnO
BnO
O
N3
BnO
OBn
OBn
OBn
OH OH
45
O
BnO
BnO
O
N3
BnO
OBn
OBn
OBn
O OH
O
H3C(H2C)14
O
O
(CH2)14CH3
O
BnO
BnO
O
N3
BnO
OBn
OBn
OBn
OH
+
C16H31OCl, pyridine, 
DMAP, CH2Cl2, 60°C, 24 h
46
47
 
2-Azido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranosyl-(1 → 6)-3,4,5-tri-O-benzyl-1-
palmitoyl-D-myo-inositol (46) and 2-azido-3,4,6-tri-O-benzyl-2-deoxy-D-
glucopyranosyl-(1 → 6)-3,4,5-tri-O-benzyl-2-palmitoyl-D-myo-inositol (47).  To a 
solution of diol 45 (10 mg, 0.01 mmol) in distilled pyridine (21 µL, 0.25 mmol) was 
added DMAP catalyst (0.125 mg, 0.001 mmol, 10 mol %) and palmitoyl chloride (6.05 
µL, 0.02 mmol, 2 equiv*).  The reaction mixture was stirred under an argon atmosphere 
at 60 ˚C and was monitored by TLC (40 % EtOAc in heptane).  The reaction was heated 
to about 110 ˚C to accelerate the conversion of the starting material.  However, even after 
prolonged periods of reflux (36-48 h) the conversion was never completed.  Pyridine was 
evaporated under vacuum.  The reaction mixture was diluted with CH2Cl2 and washed 
successively with water (2 x 10 mL), 0.1 M HCl (1 x 10 mL), water (2 x 10 mL), 
saturated NaHCO3 (3 x 10 mL), and brine (1 x 10 mL).  The organic phase was dried 
over MgSO4, filtered, and evaporated to give a crude reaction product.  Further 
purification of the crude reaction product by PTLC (45 % EtOAc in heptane) yielded 0.3 
mg of 46 and 1.3 mg of 47, with a combined yield of 24 % (after recovery of 3.0 mg of 
starting material).  For 46: 1H NMR (400 MHz, CDCl3).
35  For 47: 1H NMR (400 MHz, 
CDCl3).
35 
  
* Excess palmitoyl chloride was added to push the reaction to completion 
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2-Azido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranosyl-(1 → 6)-1,3,4,5-tetra-O-
benzyl-D-myo-inositol (49) and 2-azido-3,4,6-tri-O-benzyl-2-deoxy-D-
glucopyranosyl-(1 → 6)-2,3,4,5-tetra-O-benzyl-D-myo-inositol (50).  A mixture of diol 
32 (10.6 mg, 12.35 µmol) and Bu2SnO (4.01 mg, 16.06 µmol, 1.3 equiv) in dry 
CH3OH/toluene (1:1 v/v, 0.2 mL) was refluxed under an argon atmosphere at 130 ˚C for 
3 h.  The solvents were evaporated, dry toluene (1 mL) was added to the residue, and a 
second evaporation to dryness under high vacuum was effected.  Then, a mixture of crude 
stannylene derivative, Bu4NBr (2.4 mg, 7.4 µmol, 0.6 equiv), and BnBr (5.2 µL, 43.23 
µmol, 3.5 equiv) in dry toluene (0.2 mL) was refluxed under an argon atmosphere at 130 
˚C.  Progress of the reaction was monitored by TLC (40 % EtOAc in hexane; for starting 
material Rf = 0.23, for products Rf = 0.58-0.67) until all the starting material was reacted, 
approximately 18 h.  The solvent was evaporated under reduced pressure, and the crude 
reaction product was purified by PTLC (10 % EtOAc in toluene) yielding 6.2 mg of pure 
49 and 1.6 mg of pure 50 with a combined yield of 64 %.  For 49: Rf = 0.28 (10 % EtOAc 
in toluene); 1H NMR (400 MHz, CDCl3) δ 3.14 (dd, J = 11.3, 2.0 Hz, 1H, GluN-H-6a), 
3.21 (dd, J = 11.2, 1.88 Hz, 1H, GluN-H-6b), 3.28 (dd, J = 10.3, 3.9 Hz, 1H, GluN-H-2), 
3.37-3.45 (m, 2H, Ino-H-3, Ino-H-5), 3.52 (dd, J = 2.5, 9.5 Hz, 1H, Ino-H-1), 3.67 (Ψt, J 
= 9.5 Hz, 1H, GluN-H-4), 3.94 (Ψt, J = 9.2, 9.3 Hz, 1H, GluN-H-3), 3.99-4.09 (m, 2H, 
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GluN-H-5, Ino-H-4), 4.17 (Ψt, J = 9.3, 9.6 Hz, 1H, Ino-H-6), 4.22 (m, 1H, Ino-H-2), 
4.24 (d, J = 11.8 Hz, 1H, PhCH2O), 4.38 (d, J = 11.0 Hz, 1H, PhCH2O), 4.51 (d, J = 12.1 
Hz, 1H, PhCH2O), 4.62 (d, J = 10.9 Hz, 1H, PhCH2O), 4.66 (d, J = 11.3 Hz, 1H, 
PhCH2O), 4.66-4.74 (m, 4H, PhCH2O), 4.82 (d, J = 10.8 Hz, 1H, PhCH2O), 4.85 (d, J = 
10.5 Hz, 1H, PhCH2O), 4.88 (d, J = 11.0 Hz, 1H, PhCH2O), 4.95 (d, J = 10.6 Hz, 1H, 
PhCH2O), 4.98 (d, J = 10.7 Hz, 1H, PhCH2O), 5.69 (d, J = 3.8 Hz, 1H, GluN-H-1), 7.00-
7.43 (m, 42H, PhCH2O).  HRMS (ESI): m/z calcd for C61H63O10N3: 998.4586. Found: 
998.4577.  For 50: Rf = 0.44 (10 % EtOAc in toluene); 
1H NMR (400 MHz, CDCl3) δ 
3.03 (dd, J = 11.0, 2.0 Hz, 1H), 3.20 (dd, J = 11.3, 2.3 Hz, 1H), 3.23 (d, J = 6.3 Hz, 1H), 
3.36 (Ψt, J = 9.2 Hz, 1H), 3.44-3.52 (m, 2H), 3.61 (ddd, J = 3.6, 5.9, 13.2 Hz, 1H), 3.67-
3.76 (m, 2H), 3.86-4.03 (m, 5H), 4.38 (d, J = 11.0 Hz, 1H), 4.45 (d, J = 11.9 Hz, 1H), 
4.62 (d, J = 11.2 Hz, 1H), 4.65-4.75 (m, 4H), 4.75-4.81 (m, 2H), 4.83 (d, J = 11.4 Hz, 
1H), 4.88 (d, J = 11.7 Hz, 1H), 4.94 (d, J = 10.7 Hz, 1H), 4.98 (d, J = 11.9 Hz, 1H), 5.01 
(d, J = 11.0 Hz, 1H), 5.43 (d, J = 3.8 Hz, 1H), 6.98-7.45 (m, 42H); 1H NMR (400 MHz, 
DMSO d6) δ 3.27-3.37 (m, 63H, GluN-H-6a, GluN-H-6b, and H2O), 3.38-3.46 (m, 2H, 
GluN-H-4, GluN-H-2), 3.54 (Ψt, J = 9.9, 8.9 Hz, 1H, Ino-H-4), 3.64-3.75 (m, 2H, Ino-H-
5, Ino-H-1), 3.81-3.92 (m, 3H, GluN-H-5, Ino-H-3, Ino-H-6), 4.19 (d, J = 11.8 Hz, 1H, 
PhCH2O), 4.38 (d, J = 11.6 Hz, 1H, PhCH2O), 4.42 (d, J = 10.9 Hz, 1H, PhCH2O), 4.57-
4.64 (m, 2H, PhCH2O), 4.64-4.71 (m, 3H, PhCH2O), 4.75-4.88 (m, 6H, PhCH2O), 5.25 
(d, J = 5.9 Hz, 1H, -OH), 5.71 (d, J = 3.8 Hz, 1H, GluN-H-1), 6.96-7.45 (m, 42H, 
PhCH2O).  HRMS (ESI): m/z calcd for C61H63O10N3: 998.4586. Found: 998.4575. 
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2-Azido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranosyl-(1 → 6)-1,3,4,5-tetra-O-
benzyl-2-palmityl-D-myo-inositol (29).  To a solution of 49 (2 mg, 2 µmol) and TBAI 
(0.6 mg, 2 µmol) in dry THF (0.1 mL) was added NaH (60 % dispersion in mineral oil, 
0.2 mg, 4 µmol, 2 equiv).  Hydrogen gas was evolved in the form of bubbles.  The 
solution was allowed to stir for 20 min (note: reaction mixture should be cooled to 0 °C if 
reaction is done on large scale) after which pure 1-bromohexadecane (2 µL) was 
transferred into the reaction mixture using a syringe.  The reaction mixture was then 
refluxed at about 60 °C under an argon atmosphere until TLC (6% EtOAc in benzene) 
showed almost 80% conversion of the starting material, approximately 24 h.  THF was 
evaporated and the crude reaction mixture was purified by PTLC (7% EtOAc in benzene) 
yielding pure 29 (1.7 mg, 71%).  Rf = 0.73 (6% EtOAc in benzene).  
1H NMR (400 MHz, 
CDCl3) δ 0.77-0.98 (m, 8H, CH2CH2(CH2)12CH3 (3H)), 1.12-1.42 (m, 41H, 
CH2CH2(CH2)12CH3 (24H)), 1.44-1.75 (m, 35H, H2O), 3.12 (dd, J = 2.0, 11.0 Hz, 1H, 
GluN-H-6a), 3.19 (dd, J = 2.0, 11.3 Hz, 1H, GluN-H-6b), 3.21 (dd, J = 3.7, 10.4 Hz, 1H, 
GluN-H-2), 3.35 (dd, J = 2.3, 9.9 Hz, 1H, Ino-H-1), 3.39 (Ψt, J = 9.2, 9.4 Hz, 1H, Ino-H-
5), 3.42 (dd, J = 2.2, 9.6 Hz, 1H, Ino-H-3), 3.59-3.73 (m, 3H, GluN-H-4, GluN-H-5), 
3.83-3.88 (m, 1H, Ino-H-2), 3.94 (Ψt, J = 9.1, 10.3 Hz, 1H, GluN-H-3), 3.98-4.07 (m, 
2H, Ino-H-4, Ino-H-6), 4.15 (d, J = 9.6 Hz, 1H, PhCH2O), 4.20 (d, J = 11.9 Hz, 1H, 
PhCH2O), 4.35 (d, J = 11.5 Hz, 1H, PhCH2O), 4.52 (d, J = 11.9 Hz, 1H, PhCH2O), 4.58-
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4.67 (m, 5H, PhCH2O (4H)), 4.69 (d, J = 11.2 Hz, 1H, PhCH2O), 4.79 (d, J = 10.8 Hz, 
1H, PhCH2O), 4.82-4.89 (m, 2H, PhCH2O), 4.94 (d, J = 10.4 Hz, 1H, PhCH2O), 5.00 (d, 
J = 10.8 Hz, 1H, PhCH2O), 5.69 (d, J =4.2 Hz, 1H, GluN-H-1), 6.92-7.48 (m, 55H, 
PhCH2O (42H) + CHCl3).  HRMS (ESI): m/z calcd for C77H95O10N3: 1222.7090. Found: 
1222.7084. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  106
 
  107
 
  108
 
 
 
  109
REFERENCES: 
 
 (1) Ferguson, M. A. J.; Homans, S. W.; Dwek, R. A.; Rademacher, T. W. 
                        Science 1988, 239, 753-759. 
 (2) Low, M. G. Biochemical Journal 1987, 244, 1-13. 
 (3) McConville, M. J.; Ferguson, M. A. J. Biochemical Journal 1993, 294, 
                        305-324. 
 (4) Stevens, V. L. Biochemical Journal 1995, 310, 361-370. 
 (5) Guo, Z. W.; Bishop, L. European Journal of Organic Chemistry 2004,  
                        3585-3596. 
 (6) Low, M. G. Faseb Journal 1989, 3, 1600-1608. 
 (7) Jones, D. R.; Varela-Nieto, I. International Journal of Biochemistry & 
                        Cell Biology 1998, 30, 313-326. 
 (8) Schofield, L.; Tachado, S. D. Immunology and Cell Biology 1996, 74, 
                        555-563. 
 (9) Mayer, T. G.; Kratzer, B.; Schmidt, R. R. Angewandte Chemie- 
                        International Edition in English 1994, 33, 2177-2181. 
 (10) Campbell, A. S.; Fraserreid, B. Journal of the American Chemical Society 
                        1995, 117, 10387-10388. 
 (11) Pekari, K.; Tailler, D.; Weingart, R.; Schmidt, R. R. Journal of Organic 
                       Chemistry 2001, 66, 7432-7442. 
 (12) Ferguson, M. A. J.  1997, p 1295-1302. 
 (13) Ferguson, M. A. J. Journal of Cell Science 1999, 112, 2799-2809. 
 (14) Saltiel, A. R. Journal of Bioenergetics and Biomembranes 1991, 23, 29- 
                        41. 
 (15) Saltiel, A. R.; Cuatrecasas, P. Proceedings of the National Academy of 
                        Sciences of the United States of America 1986, 83, 5793-5797. 
 (16) Treumann, A.; Lifely, M. R.; Schneider, P.; Ferguson, M. A. J. Journal of  
                        Biological Chemistry 1995, 270, 6088-6099. 
 (17) Roberts, W. L.; Myher, J. J.; Kuksis, A.; Low, M. G.; Rosenberry, T. L. 
                        Journal of Biological Chemistry 1988, 263, 18766-18775. 
 (18) Davitz, M. A.; Hereld, D.; Shak, S.; Krakow, J.; Englund, P. T.; 
                        Nussenzweig, V. Science 1987, 238, 81-84. 
 (19) Jones, D. R.; Avila, M. A.; Sanz, C.; VarelaNieto, I. Biochemical and 
                        Biophysical Research Communications 1997, 233, 432-437. 
 (20) Misek, D. E.; Saltiel, A. R. Journal of Biological Chemistry 1992, 267, 
                        16266-16273. 
 (21) Misek, D. E.; Saltiel, A. R. Endocrinology 1994, 135, 1869-1876. 
 (22) Mato, J. M.; Kelly, K. L.; Abler, A.; Jarett, L. Journal of Biological 
                        Chemistry 1987, 262, 2131-2137. 
 (23) Larner, J.; Huang, L. C.; Schwartz, C. F. W.; Oswald, A. S.; Shen, T. Y.; 
                        Kinter, M.; Tang, G.; Zeller, K. Biochemical and Biophysical Research 
                        Communications 1988, 151, 1416-1426. 
 (24) Huang, L. C.; Fonteles, M. C.; Houston, D. B.; Zhang, C. G.; Larner, J. 
  110
                        Endocrinology 1993, 132, 652-657. 
 (25) Larner, J. Journal of Cyclic Nucleotide Research 1982, 8, 289-296. 
 (26) Low, M. G.; Saltiel, A. R. Science 1988, 239, 268-275. 
 (27) Deeg, M. A.; Humphrey, D. R.; Yang, S. H.; Ferguson, T. R.; Reinhold, 
                        V. N.; Rosenberry, T. L. Journal of Biological Chemistry 1992, 267, 
                        18573-18580. 
 (28) VarelaNieto, I.; Leon, Y.; Caro, H. N. Comparative Biochemistry and 
                        Physiology B-Biochemistry & Molecular Biology 1996, 115, 223-241. 
 (29) Larner, J.; Price, J. D.; Heimark, D.; Smith, L.; Rule, G.; Piccariello, T.; 
                        Fonteles, M. C.; Pontes, C.; Vale, D.; Huang, L. Journal of Medicinal 
                        Chemistry 2003, 46, 3283-3291. 
 (30) Saltiel, A. R. Endocrinology 1987, 120, 967-972. 
 (31) Romero, G.; Gamez, G.; Huang, L. C.; Lilley, K.; Luttrell, L. Proceedings 
                        of the National Academy of Sciences of the United States of America 1990, 
                        87, 1476-1480. 
 (32) Alvarez, J. F.; Cabello, M. A.; Kelly, K. L.; Mato, J. M.; Feliu, J. E. 
                        Diabetologia 1987, 30, A493-A493. 
 (33) Myers, M. G.; White, M. F. Annual Review of Pharmacology and  
                        Toxicology 1996, 36, 615-658. 
 (34) Saltiel, A. R. Cell 2001, 104, 517-529. 
 (35) Azev, V. N. Ph.D, Tufts University, 2007. 
 (36) Hresko, R. C.; Mueckler, M. Journal of Biological Chemistry 2005, 280, 
                        40406-40416. 
 (37) Lizcano, J. M.; Alessi, D. R. Current Biology 2002, 12, R236-R238. 
 (38) Muller, G. FEBS Lett. 2002, 531, 81-87. 
 (39) Kitamura, T.; Kitamura, Y.; Kuroda, S.; Hino, Y.; Ando, M.; Kotani, K.;  
                        Konishi, H.; Matsuzaki, H.; Kikkawa, U.; Ogawa, W.; Kasuga, M. 
                        Molecular and Cellular Biology 1999, 19, 6286-6296. 
 (40) Pilkis, S. J.; Granner, D. K. Annual Review of Physiology 1992, 54, 885- 
                        909. 
 (41) Alvarez, J. F.; Sanchezarias, J. A.; Guadano, A.; Estevez, F.; Varela, I.; 
                        Feliu, J. E.; Mato, J. M. Biochemical Journal 1991, 274, 369-374. 
 (42) Turner, D. I.; Chakraborty, N.; d'Alarcao, M. Bioorganic & Medicinal 
                        Chemistry Letters 2005, 15, 2023-2025. 
 (43) Larner, J.; Huang, L. C.; Suzuki, S.; Tang, G.; Zhang, C.; Schwartz, C. F. 
                        W.; Romero, G.; Luttrell, L.; Kennington, A. S. Annals of the New York 
                        Academy of Sciences 1989, 573, 297-305. 
 (44) Muller, G.; Wied, S.; Frick, W. Molecular and Cellular Biology 2000, 20, 
                        4708-4723. 
 (45) Muller, G.; Jung, C.; Frick, W.; Bandlow, W.; Kramer, W. Archives of  
                        Biochemistry and Biophysics 2002, 408, 7-16. 
 (46) Muller, G.; Hanekop, N.; Kramer, W.; Bandlow, W.; Frick, W. Archives  
                        of Biochemistry and Biophysics 2002, 408, 17-32. 
 (47) Smart, E. J.; Graf, G. A.; McNiven, M. A.; Sessa, W. C.; Engelman, J. A.; 
  111
                        Scherer, P. E.; Okamoto, T.; Lisanti, M. P. Molecular and Cellular 
                        Biology 1999, 19, 7289-7304. 
 (48) Muller, G.; Frick, W. Cellular and Molecular Life Sciences 1999, 56, 945- 
                        970. 
 (49) Plourde, R.; Dalarcao, M.; Saltiel, A. R. Journal of Organic Chemistry 
                        1992, 57, 2606-2610. 
 (50) Cobb, J. E.; Johnson, M. R. Tetrahedron 1991, 47, 21-30. 
 (51) Ley, S. V.; Yeung, L. L. Synlett 1992, 997-998. 
 (52) Frick, W.; Bauer, A.; Bauer, J.; Wied, S.; Muller, G. Biochemistry 1998, 
                        37, 13421-13436. 
 (53) Kornienko, A.; Turner, D. I.; Jaworek, C. H.; d'Alarcao, M. Tetrahedron- 
                        Asymmetry 1998, 9, 2783-2786. 
 (54) Kornienko, A.; d'Alarcao, M. Tetrahedron-Asymmetry 1999, 10, 827-829. 
 (55) Jaworek, C. H.; Iacobucci, S.; Calias, P.; d'Alarcao, M. Carbohydrate 
                        Research 2001, 331, 375-391. 
 (56) Chakraborty, N.; d'Alarcao, M. Bioorganic & Medicinal Chemistry 2005, 
                        13, 6732-6741. 
 (57) McLean, P.; Kunjara, S.; Greenbaum, A. L.; Gumaa, K.; Lopez-Prados, J.;  
                        Martin-Lomas, M.; Rademacher, T. W. Journal of Biological Chemistry 
                        2008, 283, 33428-33436. 
 (58) Goel, M.; Azev, V. N.; dâ€™Alarcao, M. Future Medicinal Chemistry 
                        2009, 1, 95-118. 
 (59) Reddy, K. K.; Falck, J. R.; Capdevila, J. Tetrahedron Letters 1993, 34, 
                        7869-7872. 
 (60) Jones, D. R.; Varela-Nieto, I. Molecular Medicine 1999, 5, 505-514. 
 (61) Bevan, P. Journal of Cell Science 2001, 114, 1429-+. 
 (62) Saltiel, A. R.; Kahn, C. R. Nature 2001, 414, 799-806. 
 (63) Wagman, A. S.; Nuss, J. M. Current Pharmaceutical Design 2001, 7, 417- 
                        450. 
 (64) d'Alarcao, N. C. M. 
 (65) Gottschalk, W. K.; Jarett, L. Archives of Biochemistry and Biophysics 
                        1988, 261, 175-185. 
 (66) Pelicano, H.; Martin, D. S.; Xu, R. H.; Huang, P. Oncogene 2006, 25, 
                        4633-4646. 
 (67) Gatenby, R. A.; Gillies, R. J. Nature Reviews Cancer 2004, 4, 891-899. 
 (68) King, A.; Selak, M. A.; Gottlieb, E. Oncogene 2006, 25, 4675-4682. 
 (69) Warburg, O. Science 1956, 123, 309-314. 
 (70) Gambhir, S. S. Nature Reviews Cancer 2002, 2, 683-693. 
 (71) Kroemer, G. Oncogene 2006, 25, 4630-4632. 
 (72) Carew, J. S., Huang, P. Molecular Cancer 2002, 1-9. 
 (73) Robey, R. B.; Hay, N. Oncogene 2006, 25, 4683-4696. 
 (74) Elstrom, R. L.; Bauer, D. E.; Buzzai, M.; Karnauskas, R.; Harris, M. H.; 
                        Plas, D. R.; Zhuang, H. M.; Cinalli, R. M.; Alavi, A.; Rudin, C. M.; 
                        Thompson, C. B. Cancer Research 2004, 64, 3892-3899. 
  112
 (75) Rempel, A.; Mathupala, S. P.; Griffin, C. A.; Hawkins, A. L.; Pedersen, P. 
                        L. Cancer Research 1996, 56, 2468-2471. 
 (76) Debatin, K. M.; Poncet, D.; Kroemer, G. Oncogene 2002, 21, 8786-8803. 
 (77) Gatenby, R. A.; Gillies, R. J. International Journal of Biochemistry & Cell 
                        Biology 2007, 39, 1358-1366. 
 (78) Smith, T. K.; Sharma, D. K.; Crossman, A.; Brimacombe, J. S.; Ferguson, 
                        M. A. J. Embo Journal 1999, 18, 5922-5930. 
 (79) Khan, N.; Afaq, F.; Mukhtar, H. Carcinogenesis 2007, 28, 233-239. 
 (80) Mitsunobu, O. Synthesis-Stuttgart 1981, 1-28. 
 (81) Parker, R. E.; Isaacs, N. S. Chemical Reviews 2002, 59, 737-799. 
 (82) Luchetti, G.; Ding, K. J.; d'Alarcao, M.; Kornienko, A. Synthesis-Stuttgart 
                        2008a, 3142-3147. 
 (83) David, S.; Hanessian, S. Tetrahedron 1985, 41, 643-663. 
 (84) Goncalves, A. G.; Noseda, M. D.; Duarte, M. E. R.; Grindley, T. B. 
                        Carbohydrate Research 2005, 340, 2245-2250. 
 (85) Kolb, H. C.; Vannieuwenhze, M. S.; Sharpless, K. B. Chemical Reviews 
                        1994, 94, 2483-2547. 
 (86) Martin-Lomas, M.; Flores-Mosquera, M.; Chiara, J. L. European Journal 
                        of Organic Chemistry 2000, 1547-1562. 
 (87) Dietrich, H.; Espinosa, J. F.; Chiara, J. L.; Jimenez-Barbero, J.; Leon, Y.; 
                        Varela-Nieto, I.; Mato, J. M.; Cano, F. H.; Foces-Foces, C.; Martin- 
                        Lomas, M. Chemistry-a European Journal 1999, 5, 320-336. 
 (88) Nashed, M. A.; Anderson, L. Tetrahedron Letters 1976, 3503-3506. 
 (89) Simas, A. B. C.; Pais, K. C.; da Silva, A. A. T. Journal of Organic 
                        Chemistry 2003, 68, 5426-5428. 
 (90) Srinivasan, K.; Michaud, P.; Kochi, J. K. Journal of the American 
                        Chemical Society 1986, 108, 2309-2320. 
 (91) Palucki, M.; Pospisil, P. J.; Zhang, W.; Jacobsen, E. N. Journal of the 
                        American Chemical Society 1994, 116, 9333-9334. 
 (92) Jacobsen, E. N.; Zhang, W.; Muci, A. R.; Ecker, J. R.; Deng, L. Journal of 
                        the American Chemical Society 1991, 113, 7063-7064. 
 (93) Adam, W.; Bialas, J.; Hadjiarapoglou, L. Chemische Berichte 1991, 124,  
                        2377-2377. 
 (94) Murray, R. W.; Jeyaraman, R. Journal of Organic Chemistry 1985, 50,  
                        2847-2853. 
 (95) Freccero, M.; Gandolfi, R.; Sarzi-Amadè, M.; Rastelli, A. Tetrahedron 
                        1998, 54, 6123-6134. 
 (96) Tsuda, T.; Nakamura, S.; Hashimoto, S. Tetrahedron 2004, 60, 10711- 
                        10737. 
 (97) Wang, D. P.; Wang, M.; Zhang, R.; Wang, X. N.; Gao, A. P.; Ma, J.; Sun,  
                         L. C. Applied Catalysis a-General 2006, 315, 120-127. 
 (98) Dueno, E. E.; Chu, F.; Kim, S.-I.; Jung, K. W. Tetrahedron Letters 1999, 
                        40, 1843-1846. 
 (99) Dijkstra, G.; Kruizinga, W. H.; Kellogg, R. M. Journal of Organic 
  113
                        Chemistry 1987, 52, 4230-4234. 
 (100) Salvatore, R. N.; Nagle, A. S.; Schmidt, S. E.; Jung, K. W. Organic 
                        Letters 1999, 1, 1893-1896. 
 (101) Yan, R. B.; Yang, F.; Wu, Y. F.; Zhang, L. H.; Ye, X. S. Tetrahedron 
                        Letters 2005, 46, 8993-8995. 
 (102) Orgueira, H. A.; Bartolozzi, A.; Schell, P.; Litjens, R.; Palmacci, E. R.; 
                        Seeberger, P. H. Chemistry-a European Journal 2003, 9, 140-169. 
 (103) Cottaz, S.; Brimacombe, J. S.; Ferguson, M. A. J. Carbohydrate Research 
                        1995, 270, 85-91. 
 (104) Luchetti, G.; Ding, K. J.; Kornienko, A.; d'Alarcao, M. Synthesis-Stuttgart  
                        2008, 3148-3154. 
 
 
